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ABSTRACT 
Triacylglycerols are the predominant storage form of energy in eukaryotes. As obesity 
has become a worldwide problem and excessive accumulation of triacylglycerols in adipose 
tissue causes obesity, enzymes catalyzing the synthesis of triacylglycerols are of great interest. 
Acyl CoA:diacylglycerol acyltransferase (DGAT), including the isoforms DGAT1 and DGAT2, 
catalyze the final and committed step in triacylglycerol synthesis. Proteins that physically 
interact with DGAT1 may provide information regarding the metabolic role of DGAT1. We 
chose HEK-293T cell line to express DGAT1 and used mass spectrometry to identify proteins 
that co-immunoprecipitated with DGAT1. We confirmed that DGAT2 and ACAT1 did interact 
with DGAT1. The interaction of DGAT1 with DGAT2 appeared to interrupt the synthesis of 
triacylglycerol since the co-expression of DGAT1 and DGAT2 was expected to increase 
triacylglycerol synthesis. This implied that DGAT1 and DGAT2 might serve different functional 
roles. On the other hand, DGAT1 overexpression may increase the synthesis of cholesterol esters 
that was the product of ACAT1. Additionally, ACAT1 overexpression did increase 
triacylglycerol synthesis and ACAT1 disruption by siRNA did decrease triacylglycerol synthesis. 
Our findings indicated that DGAT1 and ACAT1 might be involved in the same lipid-
synthesizing protein complex. 
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1. INTRODUCTION 
 
Triacylglycerols (TGs) are the major form of stored energy in animals, plant seeds and 
microorganisms. TGs are composed of a glycerol backbone and three fatty acids (FAs, 
carboxylic acids with chain containing 4 to 36 carbons) attached by ester bonds (Lehner and 
Kuksis, 1996). TGs are highly reduced. Oxidation of TGs yields more than twice the free energy 
relative to an equal mass of carbohydrate. Moreover, TGs are anhydrous and hence lighter, 
unlike polysaccharides, which need to carry the extra weight of water for hydration (2 g water 
per gram of polysaccharide). Due to these advantages, almost all tissues have the ability to 
synthesize TGs, although adipose tissue is the main place for TG storage. Excessive 
accumulation of TG in adipose tissue leads to obesity and obesity-related disorders, such as 
diabetes and cardiovascular disease. In order to prevent the excessive accumulation of TG, it is 
of importance to study the synthesis of TG. 
In mammals, there are two different pathways to synthesize TGs, the monoacylglycerol 
pathway and the glycerol-3-phosphate pathway (Kennedy, 1957; Bell and Coleman, 1980). The 
committed step for TG synthesis in both pathways is the conversion of diacylglycerol (DG) to 
TG, catalyzed by acyl-CoA:diacylglycerol acyltransferase (DGAT). Two different DGAT 
enzymes have been identified, DGAT1 and DGAT2. Although they catalyze the same reaction, 
DGAT1 and DGAT2 have distinct physiological functions. DGAT1 and DGAT2 are from 
different gene families and share no sequence similarity at all. Moreover, DGAT1 possesses 
multiple enzyme activities, such as acyl-CoA:monoacylglycerol acyltransferase (MGAT), wax 
synthase and acyl-CoA:retinol acyltransferase (ARAT) activity (Yen et al., 2005). In contrast, 
DGAT2 only has DGAT activity. Physiological studies revealed that DGAT2 is the key enzyme 
for bulk TG synthesis, as DGAT2 deficiency is lethal to mice (Stone et al., 2004). On the 
contrary, DGAT1 deficient mice are viable (Smith et al., 2000).  
Through the use of molecular tools, much progress has been made in understanding 
DGAT biochemical and cellular functions. However, TG synthesis and its incorporation into 
lipid droplets and secretion into the bloodstream are still poorly characterized cellular events. 
Since almost every cellular process requires protein-protein interactions, we hypothesize that 
DGAT1 and DGAT2 interact with other proteins to promote the efficient synthesis of TG. The 
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objectives of my MSc research studies were to identify DGAT-interacting proteins and examine 
the roles of them in TG synthesis, storage and/or secretion.  
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2. LITERATURE REVIEW 
 
 
2.1 Triacylglycerol 
 
Triacylglycerols (TGs) belong to the class of neutral lipids. A TG molecule is composed 
of glycerol with all three glycerol hydroxyl groups esterified by a fatty acyl group. Fatty acids 
consist of a hydrocarbon chain with a terminal carboxyl group. Fatty acids vary in length, shape 
(straight, branched or ringed) and degree of unsaturation (number of double bonds). In mammals, 
the fatty acyl chains in the C1 positions of TG are usually straight and saturated. The fatty acyl 
chain in position 3 of the glycerol backbone is variable, and the most common forms are 
saturated and monounsaturated fatty acids. 
Different species, such as many types of bacteria and yeast, seeds of plants and most 
animals utilize TG as a major form of energy storage (Alvarez and Steinbuchel, 2002; Sorger and 
Daum, 2002; Hobbs et al., 1999; Cases et al., 1998a). There are several advantages for 
organisms to choose TG over starch or glycogen. First, TGs are highly reduced and reserve more 
energy compared to sugars or proteins. Completely oxidizing 1 molecule of glucose, glutamine 
or palmitate (a fatty acid with 16 carbons) produces 38, 24 and 106 molecules of ATP, 
respectively (Vasta et al., 1993). Secondly, TGs are highly hydrophobic that decreases storage 
mass. On the contrary, every gram of glycogen needs to bind 2 grams of water. Also, TGs are 
chemically inert and do not react with other molecules. 
In humans, TGs are stored in most organs, such as white adipose tissue, liver, muscle and 
kidney. But TGs are mainly deposited in the white adipose tissue, which is widely distributed 
under the skin, in the mammary gland and the abdominal cavity. Adipocytes are specialized cells 
in white adipose tissue responsible for TG synthesis and storage. The characteristic feature of 
adipocytes is that in the cell, a single large lipid droplet containing TGs takes up most of the 
intracellular space. TGs in various tissues are obtained from the diet or synthesized, de novo. The 
general absorption of dietary TGs are described in Figure 2.1. After having a fatty meal, bile 
salts emulsify dietary fats in the small intestine. Pancreatic lipase then hydrolyzes TGs into 2-
monoacylglycerol (2-MG) and fatty acids, both of which are taken up by enterocytes and re-
esterified by DGAT into TGs.  
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Figure 2.1. Absorption and transport of TG. TGs are hydrolyzed in the small intestine, 
transported into enterocytes, packaged into chylomicrons, and transferred to tissues for fuels, 
storage and other purposes. Excessive TGs in the liver are transported in VLDLs to adipose and 
muscle tissue through the blood vessels. Lipoprotein lipase in the vessels hydrolyzes TGs in 
chylomicrons and VLDLs to release free fatty acids. Chylomicrons thus become chylomicron 
remnants, and VLDLs become IDLs and LDLs. Remnants, IDLs and LDLs finally move to the 
liver. Some LDLs are delivered to extrahepatic tissues, which can secrete HDLs containing TGs 
and cholesterol in the liver. “E” in the lipid particle resembles the TGs with three fatty acids 
attached to the glycerol backbone. “I” resembles the released fatty acids from TGs. 
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Lipases break down TGs. FAs are converted to TGs. 
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TGs and other lipids are combined with an apolipoprotein ApoB48, and packaged into 
lipoprotein complexes called chylomicrons. Chylomicrons are secreted to lymph and enter into 
systemic circulation. In the capillaries in adipose tissues, TGs contained in chylomicrons are 
hydrolyzed into glycerol and fatty acids by lipoprotein lipase. In the process of releasing TGs, 
chylomicrons become chylomicron remnants and finally travel to the liver. The hydrolyzed fatty 
acids are taken up by adipocytes and incorporated into TGs for storage. 
Excessive TGs in the liver are also packaged into very low-density lipoprotein (VLDL). 
The TG-rich VLDLs then transport TGs to adipose tissue for storage. By giving up TG, VLDL 
becomes the intermediate-density lipoprotein (IDL) and low-density lipoprotein (LDL), and is 
finally transported back to the liver. The weight percentages of TG in chylomicrons, VLDLs, 
IDLs and LDLs are 85%, 50%, 31% and 10%, respectively. Besides, the liver, the small intestine 
also secrete high-density lipoprotein (HDL) precursors to enable the formation of HDL by 
extrahepatic tissues. The resultant HDLs are transported back to the liver to recycle cholesterol 
and a relatively small amount of TGs from other tissues. The weight percentage of TG in HDLs 
is about 4%. 
When animals undergo vigorous physical activity, starvation or fasting, glucose from 
glycogen is rapidly used up. TGs stored in adipocytes are then broken down to fatty acids by 
hormone sensitive lipase. Fatty acids are released into blood, bound to serum albumin followed 
by transport to various tissues, such as the liver, muscles and kidneys (Figure 2.2). After arriving 
at these tissues, fatty acids are detached from albumin to translocate into cells by transporter 
proteins in the plasma membrane. The brain cannot utilize fatty acids directly and high levels of 
plasma fatty acids are toxic, so circulating fatty acids are converted to ketone bodies by the liver 
to serve as metabolic fuel for β-oxidation. Besides dietary fats, TGs can also be derived de novo 
from glucose. The biosynthesis of TGs not only conserves the energy contained in glucose, but 
also serves important physiological functions.  
Both high serum levels of fatty acids or glucose can lead to reactive oxygen species and 
insulin resistance (Inoguchi et al., 2000; Groop et al., 1989). Thus, excessive glucose needs to be 
incorporated into fatty acids, which are then incorporated into TG to maintain plasma glucose 
and fatty acid levels (Unger and Grudy, 1985). 
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Excessive accumulation of TGs in adipose tissue, liver, heart and pancreatic beta cells is 
associated with obesity, insulin resistance and type II diabetes mellitus in humans (Unger, 2002). 
The prevalence of obesity has increased remarkably over the last twenty years. In Canada, ~65% 
of Canadian adults are considered overweight and ~25% are obese (Tjepkema et al., 2009). 
Obese individuals are at risk for diabetes and cardiovascular disease. To better prevent obesity 
and obesity-associated disorders, an understanding of TG biosynthesis is of biomedical 
importance. 
Peripheral Tissues:        
Muscle, Kidney 
KB               CO2           Glucose        
Brain 
Glucose                    CO2 
       KB                       CO2 
 
Adipose Tissue 
FA                              TG 
Liver 
Glycogen                   Glucose 
FA                                KB 
FA 
Glucose 
 FA 
KB 
Figure 2.2. The utilization of TG under nutritional stress. Glycogen is broken down to supply 
glucose under the fasting condition. When glycogen is used up, TG in adipose tissue is then 
broken down into FA and transported to other tissues as the fuel. The brain cannot use FA, so a 
part of FAs are converted into ketone bodies (KB) for energy supply. 
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2.2 Triacylglycerol Biosynthesis and Acyl-CoA:Diacylglycerol Acyltransferase (DGAT) 
 
TG biosynthesis occurs via either the monoacylglycerol pathway in the intestine or 
glycerol phosphate pathway (de novo synthesis, also called Kennedy pathway) (Figure 2.3) 
(Kennedy, 1957; Bell and Coleman, 1980; Lehner and Kuksis, 1996). For the monoacylglycerol 
pathway, water-insoluble dietary fats have to be emulsified and hydrolyzed to 2-
monoacylglycerol and fatty acids prior to passing through the intestinal lumen. 
Monoacylglycerol and fatty acids are re-synthesized by MGAT or DGAT1 into 1,2-
diacylglycerol that are subsequently converted into TGs by DGAT, and packaged into 
chylomicrons for the distribution of TG to tissues. For the de novo synthesis of TG, the source of 
fatty acids and glycerol backbone can be either synthesized by the cell itself or from diet directly. 
To initiate TG biosynthesis, fatty acids have to be activated by acyl-CoA synthetase into 
their acyl-CoA derivatives. Glycerol-3-phosphate (G3P) is then esterified with acyl-CoA by 
glycerol phosphate acyl-CoA acyltransferase (GPAT) to yield lysophosphatidate (LPA) (Figure 
2.3). The second acylation reaction is catalyzed by lysophosphatidate acyltransferase (LPAT) to 
generate phosphatidate (PA) from LPA. Next, the phosphate group of PA is hydrolyzed by 
phosphatidate phosphatase (PAP) to generate 1,2-diacylglycerol, which is used by DGAT with a 
third acyl-CoA to generate the TG (Figure 2.4A) (Coleman and Lee, 2004; Vance and Brindley, 
1991). In addition, diacylglycerol can also be used to synthesize phospholipids such as 
phosphatidylethanolamine (PE) and phosphatidylcholine (PC). Specifically, phosphatidylcholine 
is different from phosphatidylethanolamine by containing additional three methyl groups in its 
amino group. GPAT localizes in both ER and mitochondria, LPAT localizes in ER and PAP is 
present in the cytosol and plasma membrane (Coleman and Lee, 2004). When cells are loaded 
with fatty acids cytosolic, PAP translocates to the ER membrane. Two DGAT enzymes have 
been identified, DGAT1 and DGAT2. Both DGAT1 and DGAT2 are expressed at high levels in 
tissues active in TG synthesis, such as white adipose tissue, small intestine, mammary gland and 
liver. DGAT1 and DGAT2 are very different enzymes and are encoded by unrelated genes that 
share no sequence similarity and have different physiological roles (Yen et al., 2008). DGAT2 
localizes to ER and mitochondria, while DGAT1 and LPAT are only found in ER. 
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Figure 2.3. TG synthetic pathways. Major key enzymes in TG synthetic pathways and their 
substrates and products. G3P, glycerol 3-phosphate. GPAT, glycerol 3-phosphate 
acyltransferase. LPA, lysophosphatidate. LPAT, acyl-CoA:lysophosphatidate acyltransferase. 
PAP, phosphatidate phosphatase. DGAT, acyl-CoA:diacylglycerol acyltransferase. PA, 
phosphatidate. PE, phosphatidylethanolamine. PC, phosphatidylcholine. TG, triacylglycerol. 
DG, diacylglycerol. MG, monoacylglycerol. MGAT, acyl-CoA:monoacylglycerol 
acyltransferase. 
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2.3 DGAT1 
 
2.3.1 DGAT1 Gene Family 
 
Although the TG biosynthetic pathway and DGAT activity were described in the 1950s 
by Kennedy et al. (Kennedy, 1957), the gene for DGAT1 has only been recently identified due to 
its homology to acyl-CoA:cholesterol acyltransferase (ACAT) enzymes (Cases et al., 1998a). 
ACAT enzymes catalyze the formation of cholesterol esters (CE) from cholesterol and fatty acyl-
CoA (Figure 2.4B). Murine DGAT1 has ~20% sequence identity relative to murine ACAT1, 
mostly at the C-terminus. DGAT1 orthologs have also been identified in many different species. 
DGAT1 is a member of the membrane-bound O-acyltransferase protein family (MBOAT) 
(Hofmann, 2000). MBOAT protein members catalyze O-acylation reactions that transfer fatty 
acyl-CoA onto the hydroxyl or thiol groups of lipid and protein acceptors. 
 
A. B. 
Figure 2.4. Biosyntheses of TG and cholesterol ester. (A) Diacylglycerol is esterified with 
fatty acyl-CoA by DGAT enzymes to form a triacylglycerol. (B) Cholesterol is esterified 
with fatty acyl-CoA by ACAT. 
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2.3.2 Structure and Biochemistry of DGAT1 
 
DGAT1 from mammalian species contains approximately 500 amino acids (Cases et al., 
1998a). It is an integral membrane protein localized to the ER and found capable of existing in 
oligomeric forms such as a dimer and tetramer (Cheng et al., 2001). In a recent study, murine 
DGAT1 was found to contain three transmembrane domains with the N-terminus oriented 
toward the cytoplasm and the C-terminus containing the active site projecting into the ER lumen 
(McFie et al., 2010) (Figure 2.5). 
The N-terminus of DGAT1 appears to be required for dimer/tetramer formation 
(Weselake et al., 2006; McFie et al., 2010). It is not clear whether a higher order structure of 
DGAT1 is functionally significant for its catalytic activity. Cross-linking experiments showed 
that the active form of DGAT1 might be a dimer, and the deletion of amino acids 37-84 prevents 
tetramer formation and increased DGAT activity seven-fold. In the C-terminus, His-426 of 
DGAT1 was shown to be essential for enzymatic activity and to be part of the active site.  
 
 
 
Figure 2.5. Model of the murine DGAT1 membrane topology. DGAT1 contains three 
transmembrane domains. Its N-termini faces the cytosolic side of ER and its C-termini faces 
the lumen side of ER. The circle with H letter indicates the active site histidine at position 
426. The cytosol and ER lumen sides are indicated. The first transmembrane domain of 
DGAT1 extends from amino acid 97 to 118. The second and third transmembrane domains of 
DGAT1 extend from 230-240 and 240-250. 
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Human ACAT1 and ACAT2 also have highly conserved histidine residues in their active 
site regions (Guo et al., 2005; Das et al., 2008). Since the active site of DGAT1 was shown to be 
present in the ER lumen, it is possible that TG produced by DGAT1 could be channeled to 
nascent lipoproteins. However, the functional role of DGAT1 in the secretion of TG-rich VLDL 
is unclear. Some studies have shown a positive correlation between DGAT1 overexpression and 
increased VLDL secretion from the liver (Millar et al., 2006; Yamazaki et al., 2005; Liang et al., 
2004), while a separate study showed that DGAT1 knockdown did not affect plasma VLDL 
levels in mice (Liu et al., 2008). 
The substrate specificity of DGAT1 has not been carefully examined. It appears that 
DGAT1 prefers monounsaturated fatty acyl-CoA, such as oleoyl-CoA (18:1) as a substrate. 
There is also a preference for diacylglycerol containing monounsaturated fatty acids as well 
(Cases et al., 2001; Hiramine and Tanabe, 2011). Apart from DGAT activity, DGAT1 has 
additional acyl-CoA dependent acyltransferase activities, including acyl-CoA:retinol 
acyltransferase (ARAT) activity, acyl-CoA:monoacylglycerol acyltransferase (MGAT) activity 
and wax synthase activity (Yen et al., 2005). MGAT activity is capable of esterifying a 
monoacylglycerol with one fatty acyl-CoA to generate diacylglycerol. DGAT1 prefers 2-
monoacylglycerol over 3- monoacylglycerol as a substrate to synthesize 1,2- diacylglycerol, the 
preferred substrate for DGAT1 and DGAT2  (Hiramine and Tanabe, 2011). This function of 
DGAT1 is particularly favored in the small intestine where the high activity events of TG 
hydrolysis and re-esterification occur. When rats were orally fed with a DGAT1 inhibitor XP620 
that specifically suppressed DGAT1’s MGAT activity, lipid absorption through the intestine was 
reduced ~50% (Cheng et al., 2008). However, DGAT1 was not essential for quantitative dietary 
TG absorption. DGAT1-deficient mice absorbed the same amount of dietary TG as wild-type 
mice, although they secreted TG into the circulation at a reduced rate (Buhman et al., 2002). 
Other enzymes such as DGAT2 and diacylglycerol transacylase were suggested to compensate 
for the lack of DGAT1 (Buhman et al., 2002). More interestingly, DGAT1-deficient mice 
specially designed only to express DGAT1 in the small intestine were shown to be susceptible to 
a high-fat diet induced hepatic steatosis and obesity (Lee et al., 2010). This indicated that 
DGAT1 was the preferential protein to synthesize TG and as well as stimulating TG secretion 
from enterocytes. 
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Another activity of DGAT1, ARAT activity, catalyzes the formation of retinyl esters 
from retinol (vitamin A) and fatty acyl-CoA. DGAT1 might function in assisting the absorption 
of vitamin A in intestine by converting it into retinyl esters that are incorporated into 
chylomicrons. Studies reported that Dgat1
-/-
 mice have markedly reduced ARAT activities in 
liver and adrenal gland even though there was another enzyme, lecithin:retinol acyltransferase, 
(LRAT) considered to be involved in bulk retinyl ester synthesis (Orland et al., 2005; Ball et al., 
1985). Retinol is the precursor of retinoic acid, a hormone that has a role in sebaceous gland 
function, hair growth and proliferation of mammary gland epithelial cells. Dgat1
-/-
 mice showed 
characteristics of dry fur and hair loss due to lack of retinol (Chen et al., 2002). DGAT1 also 
uses fatty alcohols and fatty acyl-CoA to form wax monoesters and diesters (Yen et al., 2005). 
Wax esters coat the skin surface of mammals to prevent water loss and abrasion (Thody and 
Shuster, 1989). Dgat1
-/-
 mice showed hair loss due to atrophy of the sebaceous glands, caused by 
a lack of wax diesters (Chen et al., 2002a). 
       
2.3.3 Physiological Roles of DGAT1 
 
DGAT1 is expressed ubiquitously in mice and humans, in organs such as small intestine, 
liver, adipose tissue and mammary gland (Cases et al., 1998a). DGAT1’s physiological roles 
were revealed by the disruption of DGAT1 expression in mice.  
The mRNA level of DGAT1 directly correlated with fat storage in mice, as shown by 
mice of different genetic backgrounds (Dgat1
-/-
, Dgat1
+/-
,
 
Dgat1
+/+
) (Chen and Farese, 2005). In 
Dgat1
-/-
 mice, the DGAT1 mRNA was not detectable and the tissue DGAT activity was 
significantly reduced in various tissues, such as adipose tissue, small intestine, liver, testes and 
brain (Smith et al., 2000). Dgat1
-/- 
mice were leaner and showed less adipose mass (~50% 
reduction), improved insulin sensitivity and glucose metabolism compared to wild-type mice 
(Smith et al., 2000; Tsai et al., 2007). TG levels in liver as well as adrenal glands decreased 
moderately in Dgat1
-/- 
mice. Dgat1
-/-
 mice were also resistant to diet-induced obesity and showed 
a decreased rate of TG absorption when challenged by a high-fat diet. Although Dgat1
-/- 
mice 
exhibited reduced white adipose tissue, the fatty acid composition of adipose tissue was similar 
between Dgat1
-/- 
mice and wild-type mice. In addition, fasting serum TG levels in Dgat1
-/-
 mice 
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were similar to those in wild-type mice. This indicated that quantitatively, the disruption of 
DGAT1 did not affect the TG secretion from livers.  
As a matter of fact, in Dgat1
-/- 
mice hepatic TG levels were similar with those in wild-
type mice with chow-fed diet (Villanueva et al., 2009). After high-fat feeding, Dgat1
-/- 
mice 
showed ~80% decrease in hepatic TG levels compared to wild-type mice. In the mice with liver-
specific knockout of DGAT1, hepatic TG levels also showed ~50% decrease. These facts 
indicated that DGAT1 disruption could reduce TG storage in the liver when challenged with 
high-fat diet, even though DGAT2 is also expressed in the liver.  
DGAT1 deficiency also has profound effects on other tissues, such as mammary glands, 
skin. Female Dgat1
-/- 
mice could not produce milk, and few lipid droplets were found in their 
mammary tissues (Smith et al., 2000). Hence, DGAT1 is essential for lactation. Dgat1
-/- 
mice 
also displayed fur abnormalities such as dryness and hair loss. This resulted from that abnormal 
sebaceous glands of Dgat1
-/- 
mice produce little type II wax diesters, could not maintain moisture 
and protect the fur of mice. The disruption of DGAT1 did not result in the malabsorption of TG 
in the intestine or abnormalities in chylomicron synthesis (Buhman et al., 2002). Dgat1
-/- 
mice 
showed a normal quantitatively dietary TG absorption, but the small intestine secreted TGs into 
the bloodstream at a lower rate compared to wild-type mice. 
 
2.4 DGAT2 
 
2.4.1 DGAT2 Gene Family 
 
Because Dgat1
-/-
 mice still have abundant TG and DGAT activity, it was thought that 
there must be another DGAT gene. In 2001, three years after the discovery of DGAT1, a second 
DGAT, DGAT2, was identified (Lardizabal et al., 2001; Cases et al., 2001). DGAT2 is in the 
DGAT2/MGAT gene family, which includes MGAT1, MGAT2, MGAT3 and wax monoester 
synthases. The protein sequence of DGAT2 shares 40-50% identity with MGAT enzymes and 
wax synthase, however, DGAT2 does not have MGAT or wax synthase activity. All DGAT2 
protein family members contain a highly conserved HPHG amino acid sequence. 
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2.4.2 Structure and Biochemistry of DGAT2 
 
In most species, DGAT2 contains 350-400 amino acids and is 42 kDa (Cases et al., 
2001). DGAT2 localizes to the ER, and is less hydrophobic compared to DGAT1 according to 
Kyte-Doolittle hydrophobicity analysis. DGAT2 has also been found on the surface of cytosolic 
lipid droplets, mitochondria and mitochondria-associated-membranes (MAM) that are the 
specialized domains of the ER associating tightly with mitochondria (Kuerschner et al., 2008; 
Stone et al., 2009). This juxtaposition of ER membrane and mitochondrial membranes is thought 
to channel lipids between ER and mitochondria. The fact that DGAT2 could redistribute around 
lipid droplets suggested that TG synthesized by DGAT2 could be directed into cytosolic lipid 
droplets for storage. 
DGAT2 appears to be more active at lower concentration of substrates (fatty acyl-CoA, 
0-50 M), unlike DGAT1 (with higher activity at >100 M), indicating DGAT2 has a higher 
affinity for fatty acyl-CoA. One study reported that DGAT2 appeared to utilize fatty acids from 
de novo synthesis, since stearoyl-CoA desaturase 1 (SCD1) deficiency that disrupted substrate 
channeling to DGAT2 decreased TG synthesis (Man et al., 2006). DGAT2 from M. ramanniana 
(oleaginous fungus) shows higher activities with short- and medium-chain fatty acyl moieties 
(6:0, 8:0, and 10:0) rather than longer chains (Lardizabal et al., 2001). 
The topology of murine DGAT2 has been determined. DGAT2 is an integral membrane 
protein with two transmembrane domains and both N- and C-termini facing toward the cytosolic 
side of the ER (Figure 2.6) (Stone et al., 2006). The first transmembrane domain (TMD1) of 
DGAT2 is between amino acids 66-88, and the second one (TMD2) is between amino acids 93-
115 with the short loop between them oriented towards the ER lumen. TMD1 contains an ER 
targeting signal for DGAT2 localization to the ER (McFie et al., 2011). A DGAT2 mutant 
lacking both transmembrane domains did not localize to the ER and instead was localized to 
mitochondria. Amino acids 61-66 of DGAT2, which are exposed to the cytosol, are a 
mitochondrial targeting signal sequence. The reason for the interaction of DGAT2 with 
mitochondria is not clear (Stone et al., 2009). TMD1 also contains a conserved neutral lipid-
binding domain (amino acids 80-87, FLVLGVAC) that is also present in other enzymes involved 
in lipid metabolism such as LPAT and cholesterol ester transfer protein (CETP) (Stone et al., 
2006; Au-Young and Fielding, 1992). 
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This domain serves to bind or transfer neutral lipids. A mutation in this domain of 
DGAT2 resulted in a large decrease of DGAT activity in in vitro assays, indicating that this 
domain is important for the enzymatic activity of DGAT2 (Stone et al., 2006). 
The cytoplasmic C-terminus of DGAT2 contains the active site histidine in the highly 
conserved HPHG sequence. The enzymatic activity of DGAT2 is in the cytosolic side of the ER. 
This suggests that TG synthesized by DGAT2 would be released at the cytosolic side of the ER 
and ready to translocate into lipid droplets for storage instead of being secreted. In support of 
this, the C-terminus of DGAT2 is indicated to have a role in directing DGAT2 to lipid droplets 
(McFie et al., 2011). When the C-terminus of DGAT2 was truncated or mutated (232-250 or 
327-350), DGAT2 failed to co-localize with lipid droplets. 
 
2.4.3 Physiological Roles of DGAT2 
 
DGAT2 is expressed in most mouse/human tissues, but is highly expressed in white 
adipose tissue. DGAT2 plays a very different functional role from DGAT1 (Stone et al., 2004). 
Figure 2.6. Model of the murine DGAT2 membrane topology. DGAT2 contains two 
transmembrane domains. The short loop between the two transmembrane domains may be either 
exposed to the cytosol or reside in the ER bilayer. The mitochondria-targeting sequence (MTS) 
is in the region of amino acids 61-66. The first transmembrane domain (TMD1) is between 
amino acids 66-88 and contains an ER-targeting sequence. The lipid-binding domain is between 
amino acids 80-87 and is indicated with two stars. The second transmembrane domain (TMD2) 
is between amino acids 93-115. The conserved HPHG sequence is labeled as circles. 
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DGAT2 is more a potent enzyme for bulk TG synthesis. DGAT2 overexpression leads to more 
TG production than does DGAT1 in rat hepatoma cells. In yeast, DGAT2 accounts for the 
majority of TG produced (Sorger and Daum, 2002). From DGAT2 deficient (Dgat2
-/-
) mice, the 
functional roles of DGAT2 are well illustrated (Stone et al., 2004). Dgat2
-/-
 mice showed great 
decrease in size of adipose tissue and TG storage (~90%). Also, Dgat2
-/-
 mice had a defective 
skin permeability barrier causing rapid dehydration. As a result, Dgat2
-/-
 mice did not survive 
long after birth (only 6-8 h). In contrast, plasma TG levels and susceptibility to diet-induced 
obesity in Dgat2
+/-
 mice were similar to those of wild-type mice (Chen and Farese, 2005). 
DGAT2 is therefore the major DGAT enzyme responsible for bulk TG synthesis. 
Moreover, DGAT2 displayed a protective role in preventing lipotoxicity where excessive 
fatty acids impair the insulin signaling pathway (Unger, 2002). Enlarged TG pools usually 
accompanied more free fatty acids and fatty acid-derived metabolites, causing higher oxidant 
stress, fibrosis and hepatocyte necrosis. The overexpression of DGAT2 in the liver of transgenic 
mice led to hepatic steatosis with increased TG, diacylglycerol, ceramides and fatty acid but no 
insulin resistance (Monetti et al., 2007). In a later study, hepatic DGAT2 overexpression in 
mouse liver did result in insulin resistance of the liver (Jornayvaz et al., 2011). The latter study 
appears more plausible since the mice in the earlier study were tested 3 days postoperatively and 
latter study gave the mice 6-7 days to recover before further tests. Therefore, the first study did 
not leave enough time for the physiological function of the liver in mice to become fully 
recovered. In contrast, chronically suppression of DGAT2 expression using an anti-sense 
oligonucleotide caused hepatic fatty acid levels to increase. In this case, although the liver was 
protected from hepatic steatosis, it seemed that more liver damage, such as fibrosis, was caused 
from a high fatty acid level and resultant oxidative stress (Yamaguchi et al., 2007). Because the 
disruption of DGAT2 was lethal to mice, a clearly identified physiological role of DGAT2 could 
not be further addressed. 
 
2.5 Regulation of DGAT Enzymes 
 
In the TG biosynthetic pathway, the conversion of glycerol-3-phosphate into 
lysophosphatidate is considered rate-limiting (Dricks and Sul, 1997). However, since DGAT1 
and DGAT2 are at a branch point of the glycerol-3-phosphate pathway, regulation of these 
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enzymes may determine if substrates are used for TG or phospholipid biosynthesis (Figure 2.3) 
(Bagnato and Igal, 2003). The regulation of DGAT enzymes can occur at several levels. 
DGAT1 and DGAT2 expression can be regulated by nutritional and physiological status. 
For instance, free fatty acid release by epinephrine rosiglitazone stimulation can increase 
DGAT1 mRNA levels in 3T3-L1 adipocytes (Liu et al. 2008). On the other hand, the 
insufficiency of fatty acids could decrease DGAT2 mRNA levels when mice undergo fasting, 
DGAT2 mRNA levels in adipose tissue and liver decreased (Meegalla et al., 2002; Chen et al., 
2002b). Importantly, DGAT1 and DGAT2 expression could be regulated collaboratively or 
individually. During adipocyte differentiation, mRNA levels of DGAT1 and DGAT2 increased 
remarkably with a corresponding increase in DGAT activity (Ludwig et al., 2002; Ranganathan 
et al., 2006; Payne et al., 2007). In the case of individual regulation, glucose was suggested to 
preferentially enhance DGAT1 mRNA levels instead of DGAT2, whereas insulin specifically 
increased DGAT2 mRNA levels (Meegalla et al., 2002). Hypertrophy of adipocytes was 
associated with attenuated leptin action and increased DGAT2 mRNA levels and down-regulated 
DGAT1 mRNA levels in the adipocytes of Irs2
-/- 
mice (insulin receptor substrate, Irs; insulin 
resistant mice), leptin-deficient ob/ob mice (obesity-inducible mice) and wild type mice (Suzuki 
et al., 2005). 
Specifically, the regulation of DGAT1 and DGAT2 expression was through the MEK-
ERK signaling pathway (Wang et al., 2010; Au et al., 2003). When this signaling pathway was 
inhibited, both DGAT1 and DGAT2 mRNA levels were up-regulated. In addition, transcription 
factors, such as C/EBP or C/EBP, also regulated DGAT1 and DGAT2 mRNA levels (Payne 
et al., 2007). Specifically, increased CCAAT/enhancer binding protein β (C/EBPβ) and C/EBPδ 
levels could induce C/EBPα and peroxisome proliferator-activated receptor gamma (PPARγ), 
and the latter activated DGAT1 and DGAT2 expression. 
DGAT enzymes can also be regulated post-transcriptionally (Yu et al., 2002a; Casaschi 
et al., 2004; Waterman et al., 2002). In mature adipocytes (3T3-L1) overexpressing human 
DGAT1, a 7-fold increase in DGAT1 mRNA corresponded to a 90-fold increase in DGAT1 
protein. In contrast, forced DGAT1 expression in preadipocytes resulted in a 20-fold increase in 
DGAT1 mRNA only resulted in 2.6-fold increase in DGAT1 protein. This observation suggested 
that the post transcriptional regulation of DGAT1 decides both its enzyme activity and 
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intracellular TG accumulation. Though the mechanism of post-transcriptional control is not well 
understood, several phosphorylation events by cAMP-dependent or Ca
2+
 calmodulin-dependent 
protein kinases were shown to enhance DGAT activity about 20-fold in parotid gland cells from 
guinea pigs (Soling et al., 1989; Maziere et al., 1986). Protein kinase A is a known cAMP-
dependent protein kinase, and our lab has observed that protein kinase A (PKA) inhibits DGAT1, 
likely by phosphorylating the protein (unpublished observation, S. Stone and R. Farese). Like 
protein kinase A, protein kinase C is also a Ser/Thr kinase, and DGAT2 contains a protein kinase 
C (PKC) phosphorylation site that localizes in a glycerol phospholipid domain involved in the 
active site (TL, 301-302) of the acyltransferase reaction (Cases et al., 2001). Therefore, the 
regulation by phosphorylation of Ser/Thr sites in DGAT enzymes might be important for the 
control of DGAT activity. 
Besides Ser/Thr phosphorylation sites, a tyrosine protein kinase phosphorylation site is 
also thought to regulate DGAT activity. One conserved tyrosine phosphorylation site (316) in 
human DGAT1 was proposed to regulate the enzymatic activity of DGAT1. However, a later 
experiment showed that the mutagenesis of the tyrosine site did not significantly change the 
activity of the enzyme or overall rates of TG accumulation (Lau and Rodrigeuz, 1996; Yu et al., 
2002a). In contrast, the mutation of the tyrosine phosphorylation site (392) in DGAT1 from 
Indian cress (Tropaeolum majus) caused 80-100% loss of DGAT activity (Xu et al., 2008). 
Taken together, it remains unclear that whether DGAT activity is regulated by phosphorylation 
of tyrosine 392. 
DGAT activity can be regulated by inhibitors as well (Casaschi et al., 2004; Ganji et al., 
2004). When liver hepatocellular carcinoma (HepG2) cells were treated with taxifolin, a plant 
flavonoid (a non-competitive DGAT inhibitor), DGAT activity and TG synthesis from 
microsomes significantly decreased (35% and 37%, respectively). However, DGAT1 and 
DGAT2 mRNA levels remained constant. Also, niacin (DGAT2 inhibitor) decreased DGAT 
activity of DGAT2 in a non-competitive manner without affecting DGAT2 mRNA levels (Ganji 
et al., 2004). Substrate concentration also influences DGAT activity of DGAT enzymes. High 
concentration of oleoyl-CoA (>10 µM) and 1,2-dioleoylglycerol (>125 µM) was noted to inhibit 
DGAT activity (Ganji et al., 2004). In addition, 2-bromopalmitoyl-CoA inhibited DGAT activity 
by non-competitive inhibition (Coleman et al., 1992). 
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2.6 Triacylglycerol Synthesis Protein Complex 
 
Many proteins form complexes in order to promote the efficient synthesis of products. 
Therefore, it is reasonable that DGAT1 and DGAT2 interact with other proteins as part of a TG-
synthetase protein complex. For instance, DGAT from castor bean was suggested to associate 
with acyl-CoA binding proteins as it contained a signature domain (219-247) that was common 
for such binding interactions in bacteria (He et al., 2004). Two proteins have been identified that 
interact with DGAT2. Tung tree (Vernicia fordii) glycerol 3-phosphate acyltransferase 8 
(GPAT8) was shown to interact with tung tree DGAT2 (Gidda et al., 2011). The other protein 
that interacts with DGAT2 is SCD1. SCD1 converts saturated fatty acids into mono-unsaturated 
fatty acids and directs mono-unsaturated fatty acids to DGAT2 (Man et al., 2006). 
Overexpression of SCD1 increased TG synthesis and the percentage of mono-unsaturated fatty 
acids in TGs (Listenberger et al., 2003). 
Moreover, two TG synthetase complexes have been proposed in the literature (Lehner 
and Kuksis, 1995; Gangar et al., 2001).  From detergent-solubilized rat intestinal enterocytes, a 
TG-synthesis complex was obtained upon Cibacron blue 3GA-agarose affinity chromatography 
(Lehner and Kuksis, 1995). After the purification, the complex was tested and found to possess 
acyl-CoA ligase, acyl-CoA acyltransferase (AAT), MGAT, and DGAT activities. This study 
also showed that acyl-CoA acyltransferase antibodies inhibited TG synthesis and suggested that 
AAT was responsible for transferring the fatty acyl moieties to DGAT. In support of this, the 
removal of diacylglycerol acceptors led to fatty acyl moieties releasing to water in an in vitro 
assay. Although the sequence of AAT has never been identified, immunoprecipitation of AAT 
activities caused a decrease in MGAT and DGAT activities. This finding suggested that AAT 
was part of a complex catalyzing TG synthesis. Therefore, the sequential order for acyl-moiety 
transfer was suggested to be as shown in Figure 2.7. Acyl-CoA ligase activates fatty acids into 
acyl-CoA by consuming one molecule of ATP. The resulting acyl-CoA is transferred by AAT to 
DGAT, which converts diacylglycerol to TG. 
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In yeast (Rhodotorula glutinis), a cytosolic TG biosynthetic multienzyme complex was 
reported (Gangar et al., 2001). The soluble fraction of yeast cells was separated by SDS-PAGE, 
and gels containing TG synthase were excised and purified on a gel-filtration column. The eluted 
proteins were subjected to isoelectric focusing for determining polypeptide components and 
followed by activity assays. The result showed that the complex contained almost all of the main 
enzymes required for the de novo TG synthesis including LPAT, PAP and DGAT. 
These findings provide strong evidence that DGAT enzymes are part of a protein 
complex or complexes to synthesize TG. Moreover, as DGAT1 and DGAT2 may be engaged in 
different cellular processes and conceivably have different protein partners. DGAT-interacting 
proteins might further determine dissimilar functional and physiological roles of DGAT1 and 
DGAT2. 
 
2.7 Hypothesis and Rationale 
 
Our hypothesis is that both DGAT1 and DGAT2 interact with other intracellular proteins 
and/or exist as part of a protein complex that facilitates the synthesis, storage and secretion of 
TG. 
 
Rationale 
TG synthesis and its incorporation into cytosolic lipid droplets or secretion as part of 
lipoproteins remain poorly characterized cellular events. Almost every cellular process requires 
protein-protein interactions. Therefore, it is very likely that DGAT1 and DGAT2 interact with 
FA Acyl- 
DG 
TG 
ATP ADP 
Figure 2.7. Sequential order for acyl-CoA transfer. FA is channeled through the protein 
complex for TG synthesis. AAT, acyl-CoA acyltransferase. FA, fatty acid. 
Acyl-CoA ligase AAT DGAT 
Acyl-
intermed
iate 
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other proteins either constantly or transiently to facilitate the synthesis of TG and/or its storage 
and secretion. 
 
2.8 Objectives 
 
2.8.1 Identify DGAT1 and DGAT2 Interacting Proteins 
 
DGAT1 and DGAT2 will be immunoprecipitated from cells. Interacting proteins bound 
to DGAT1 and DGAT2 will be identified by mass spectrometry. 
 
2.8.2 Examine the Roles of DGAT1/DGAT2 Interacting Proteins in TG Synthesis, Storage 
and Secretion 
 
Interacting proteins will be knocked down or overexpressed in cell culture. Their effects 
on DGAT activities and TG synthesis will be examined. 
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3. MATERIALS AND METHODS 
 
 
3.1 Reagents 
 
Analytical grade or higher reagents were used for all experiments. Names of reagents, 
suppliers and addresses of suppliers are listed in Table 3.1. 
 
Table 3.1: List of Reagents and Suppliers 
 
Reagent Supplier/address 
Common Reagents  
DNA restriction enzymes NEB/Mississauga, Ontario, Canada 
GeneRuler 1kb DNA ladder Fermentas/Burlington, Ontario, Canada 
6 DNA loading dye Fermentas/Burlington, Ontario, Canada 
T4 DNA Ligase Invitrogen/Burlington, Ontario, Canada 
CHAPS Bio Basic/Markham, Ontario, Canada 
 
Bacterial Culture Reagents  
DH5 Competent Escherichia coli Invitrogen/Burlington, Ontario, Canada 
NM522 Competent Escherichia coli Stratagene/La Jolla, California, USA 
XL 10-GOLD
 
Ultracompetent Escherichia 
coli 
Stratagene/La Jolla, California, USA 
Ampicillin Bio Basic/Markham, Ontario, Canada 
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Zeocin InvivoGen/San Diego, California, USA 
Yeast Extract EMD/Madison, Wisconsin, USA 
Tryptone Bio Basic/Markham, Ontario, Canada 
NZ Amine (casein hydrolysate) Sigma-Aldrich/Oakville, Ontario, Canada 
 
Cell Culture Reagents  
Dulbecco’s Modified Eagle’s Medium – Low 
Glucose (D6046) 
Sigma-Aldrich/Oakville, Ontario, Canada 
Fetal Bovine Serum PAA/Etobicoke, Ontario, Canada 
Antibiotic-Antimycotic (100 ) 
(Penicillin and streptomycin) 
Invitrogen/Burlington, Ontario, Canada 
Bovine Serum Albumin Sigma-Aldrich/Oakville, Ontario, Canada 
Oleic Acid Sigma-Aldrich/Oakville, Ontario, Canada 
Diacylglycerol Sigma-Aldrich/Oakville, Ontario, Canada 
Cholesterol Sigma-Aldrich/Oakville, Ontario, Canada 
Phosphatidylcholine Sigma-Aldrich/Oakville, Ontario, Canada 
Triton WR-1339 Sigma-Aldrich/Oakville, Ontario, Canada 
[
14
C]Oleoyl CoA ARC/St. Louis, Missouri, USA 
[
3
H]Glycerol ARC/St. Louis, Missouri, USA 
0.05% Trypsin-EDTA Invitrogen/Burlington, Ontario, Canada 
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Commercial Kits  
QIAprep

 Spin Miniprep Kit Qiagen/Mississauga, Ontario, Canada 
QIAquick

 Gel Extraction Kit Qiagen/Mississauga, Ontario, Canada 
QIAquick

 PCR Purification Kit Qiagen/Mississauga, Ontario, Canada 
SuperSignal

 West Pico Chemiluminescent 
Substrate 
Thermo Scientific/Rockford, Ontario, Canada 
Bio-Rad DC Protein Assay Kit Bio-Rad/Hercules, California, USA 
 
Protein Analysis Reagents  
30% Acrylamide/Bis Solution (29:1) Bio-Rad/Hercules, California, USA 
PageRuler Prestained Protein ladder Plus 
(SM1811, SM0671) 
Fermentas/Burlington, Ontario, Canada 
Autoradiography Film Deville Scientific/Metuchen, New Jersey, USA 
3 FLAG® Peptide Sigma-Aldrich/Oakville, Ontario, Canada 
Monoclonal Anti-Flag M2 Sigma-Aldrich/Oakville, Ontario, Canada 
Immobilized Protein A Thermo Scientific/Rockford, Ontario, Canada 
 
siRNA Transfection Reagents  
Opti-MEM

 I Reduced Serum Medium Invitrogen/Burlington, Ontario, Canada 
siRNA oligonucleotides Invitrogen/Burlington, Ontario, Canada 
Lipofectamine Invitrogen/Burlington, Ontario, Canada 
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Table 3.2: List of Antibodies Used for Immunoblot Analysis 
Name Dilution Supplier/Address 
Mouse Anti-FLAG 1:4000 Sigma-Aldrich/Oakville, Ontario, 
Canada 
Mouse Anti-ACAT1 1:1000 GenScript/Piscataway, New jersey, USA 
Mouse Anti-Myc 1:50 9E10 hybridoma, Stone lab 
Rabbit Anti-Myc 1:2000 Sigma-Aldrich/Oakville, Ontario, 
Canada 
 
3.2 Bacterial Strains and Media Preparations 
 
E. coli DH5, NM522 and XL 10-GOLD were used in this study for the propagation of 
plasmid DNA. They were grown in Luria-Bertani (LB) medium, which was prepared by adding 
10 g tryptone, 5 g yeast extract, 10 g NaCl dissolved in 1 L double distilled water (ddH2O). For 
LB agar plates, 15 g of agar was added to 1 L LB. Media was autoclaved for 20 minutes on the 
liquid cycle under 15 psi, and the cooled media was stored at 4 ˚C till used. If LB agar plates 
with antibiotics were required, antibiotics were added when the temperature of the LB cooled to 
~55 °C, and media was poured into Petri dishes (~25 mL/100 mm plate). The concentration of 
ampicillin was 100 μg/mL, and Zeocin was 50 μg/mL. 
NZY medium was prepared for E. coli XL 10-Gold

 Ultracompetent cells. NZY medium 
contained 10 g NZ amine (casein hydrolysate), 5 g yeast extract, 5 g NaCl with deionized H2O to 
a final volume of 1 L, and the pH of the medium was adjusted to 7.5 before autoclaving. Filter-
sterilized supplements (final concentration: 0.02 M glucose, 12.5 mM MgCl2 and 12.5 mM 
MgSO4) were added prior to use.  
Terrific Broth (TB) was used for the large-scale amplification of plasmid DNA. For 200 
mL TB, 2.4 g tryptone, 4.8 g yeast extract and 0.8 mL glycerol were added to 180 mL ddH2O. 
Media was autoclaved and after cooling was supplemented with 20 mL potassium-salt solution 
(0.17 M KH2PO4 and 0.72 M K2HPO4) and the appropriate antibiotics.  
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3.3 Molecular Cloning 
 
3.3.1 Transformation of Competent Bacterial Cells 
 
E. coli DH5α and XL 10-Gold ultracompetent bacteria were transformed according to 
the supplied protocol. For the transformation of E. coli NM522, cells were first thawed in a 37˚C 
water bath, and 100 μL of cell stock was aliquoted into an ice-cold 13 mL sterile polypropylene 
tube. 5-50 ng DNA was added to the bacteria and the mixture was kept on ice for 10-30 minutes. 
The transformation mixture was heat shocked at 42 ˚C for 2 minutes, put on ice for another 2 
minutes and subsequently plated out onto LB plates with appropriate antibiotics. The plate was 
incubated at 37 ˚C overnight. 
 
3.3.2 Small Scale Plasmid DNA Preparations 
 
Small scale plasmid DNA was prepared by first inoculating single bacterial colonies of 
interest into 5 mL TB with appropriate antibiotics. Cultures were then grown overnight at 37 ˚C 
with vigorous shaking. Plasmid DNA was prepared by using a Miniprep kit (QIAprep) and 
following the manufacturer’s protocol. 
 
3.3.3 Large Scale Plasmid DNA Preparations 
 
Single colonies were picked and inoculated into 5 mL TB overnight at 37 ˚C.  The 
subsequent culture was then transferred into 200 mL TB to grow overnight at 37 ˚C with 
vigorous shaking. The extraction of plasmid DNA was as described by the protocol of Sambrook 
and Fritsch et al. (1989).  
 
3.3.4 Plasmids 
 
The following describes plasmids used in the research. LacZ, N-terminal FLAG-tagged 
murine DGAT1 (FL-DGAT1) and DGAT2 (FL-DGAT2) were cloned individually into the 
eukaryotic expression vector pcDNA3.1 (Invitrogen). FL-DGAT2 and Myc-DGAT1 were cloned 
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together into multiple cloning sites of eukaryotic expression vector pBudCE4.1. Human ACAT1 
cDNA fragment was cloned into cloning sites (BamHI/EcoRI) of pcDNA3 (Invitrogen). These 
plasmids were generous gifts from Dr. Robert Farese, Jr. (Gladstone Institutes, San Francisco). 
Various FL-DGAT1 mutants, 1-37, 38-84 and 1-85, were generated in a previous study 
using FL-DGAT1 as a template (McFie et al., 2010).  
pFLAG3 was constructed by inserting three tandem FLAG epitopes in multicloning sites 
of mammalian expression vector, pRc/CMV (Invitrogen). pMyc3 was created the same way by 
inserting three Myc epitopes. Both pFLAG3 and pMyc3 vectors were generous gifts from Dr. 
Deborah Anderson (University of Saskatchewan, Saskatchewan). All plasmids were sequenced 
to confirm the desired DNA sequence.  
 
3.3.4.1 Construction of FAR1 Plasmids 
 
A 1.5 kb fragment of human FAR1 containing the coding region was ligated into multiple 
cloning sites (NheI/ApaI) of pFLAG3 and pMyc3. This work was kindly assisted by Pam McFie. 
The following is the procedure of generating FAR1 plasmids. Human cDNA of FAR1 was 
kindly provided by Dr. David Russell (University of Texas Southwestern, Texas). 
 
3.3.4.1.1 Preparation of FAR1 cDNA 
 
Human FAR1 cDNA sequence was first amplified from pCMV-XL6 by PCR. FAR1 
cDNA was then digested as follows: 10 U of ApaI, ~2 g plasmid DNA, and 2 L proper 10 
buffer were supplemented with H2O to a final volume of 20 L. The mixture was kept at room 
temperature for 1 hour and then 10 U of NheI was added. The DNA was digested at 37 ˚C for 
another hour. 10 L of the digestion mixture was resuspended in 2 L 6 DNA loading dye and 
separated with a 1% agarose gel containing 1 g/mL ethidium bromide and 1 TAE (40 mM 
Tris-Acetate, 1 mM EDTA, pH 8). Electrophoresis was carried out for an hour at 100 volts in 1 
TAE buffer. FAR1 DNA fragments shown in the gel were excised and purified by utilizing the 
QIAquick

 Gel Extraction Kit. The procedure followed the manufacturer’s direction. 
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3.3.4.1.2 Ligation of FAR1 cDNA into pFLAG3 and pMyc3 
 
pFLAG3 and pMyc3 vectors were cleaved by NheI/ApaI, separated by agarose gel 
electrophoresis, excised, and purified by using QIAquick

 Gel Extraction Kit. The FAR1 cDNA 
was ligated into both purified pFLAG and pMyc vectors by using NheI/ApaI restriction sites. 
This part of work was kindly done by Pam McFie. The ratio of cDNA fragment and vector was 
3:1, and the ligation reaction contained 30 fmol of vector, 90 fmol FAR1 cDNA, 10 U T4 ligase 
and 4 μL 5 ligase buffer with ddH2O in a final volume of 20 L. Ligations were performed at 
14 ˚C overnight. E. coli XL-10 Gold bacteria were transformed with 2 L of the ligation 
mixture. Plasmid DNA was isolated from individual colonies and FAR1 sequence was confirmed 
by DNA sequencing (PBI-NRC, Saskatoon). 
 
3.4 Mammalian Cell Culture 
 
Human embryonic kidney 293T (HEK-293T) cells and African green monkey kidney 
cells (COS7) were used for these studies. Both cell lines were cultured at 37 ˚C with 5% CO2 in 
100 mm tissue culture plates containing high glucose Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% fetal bovine serum. HEK-293T cells were split the day before 
transfection at a ratio of 1:5. 20 g of plasmid DNA was mixed with 430 L 0.15 M NaCl, and 
120 L 0.1% polyethylenimine. The solution was gently vortexed for 10 seconds and incubated 
at room temperature for 10 minutes. The transfection mixture was added to 100 mm culture 
plates. Cells were incubated for 4 hours after which the culture plates were given fresh media. 
 
3.4.1 Oleic Acid Treatment of Cells to Stimulate TG Synthesis 
 
Oleic acid was coupled with BSA to facilitate its uptake by cells. 10% BSA (bovine 
serum albumin)/7.5 mM oleic acid stock solution was prepared as following: 5 g of fatty acid 
free BSA was dissolved in 50 mL DMEM and warmed to 56 ˚C. 0.106 g oleic acid was warmed 
to 56 ˚C and then mixed with the BSA/DMEM solution until clear. The solution was filter 
sterilized and stored at 4 ˚C. To stimulate TG synthesis, cells were incubated with 0.375 mM 
oleic acid (diluted with DMEM and 10% FBS) for 24 hours and then harvested. 
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3.4.2 Cholesterol Treatment of Cells to Stimulate Cholesterol Ester Synthesis 
 
Cholesterol was dissolved in 100% ethanol to generate a cholesterol stock solution (10 
mg/mL). For cholesterol treatment, cells in 100 mm plates were incubated with 250 g 
cholesterol at a final cholesterol concentration of 25 g/mL and oleic acid at the concentration of 
20 M for 6 hours. The addition of oleic acid is to stimulate TG synthesis. Cells were then given 
fresh media and incubated at 37 ˚C for another 24 hours and then harvested. 
 
3.4.3 siRNA Transfection 
 
siRNAs against ACAT1 were chemically synthesized (Invitrogen) and transfected into 
HEK-293T cells using Lipofectamine. The sequences of the sense siRNAs were 5-siRNA, 5’-
CAGCACACUUGUAGUAGAUUACAUU-3’ (designed for targeting 525-549 of ACAT1 
coding region mRNA) and 7-siRNA, 5’-CAUGAUCUUCAGAUUGGAGUUCUA-3’ (designed 
for targeting 744-768 of ACAT1 coding region mRNA). For 100 mm plates, 10 mL plating 
medium was incubated with 2 1 mL Opti-MEM I Reduced Serum Medium, 120 pmol siRNA 
and 20 Lipofectamine for 6 hours. Media was replaced and cells were cultured for another 48 
hours. Experiments with these siRNAs were compared to untransfected controls. Future studies 
will use a scrambled sequence. 
 
3.5 Enzyme Activity Assay 
 
3.5.1 In vitro DGAT Activity Assay 
 
HEK-293T cells were washed twice with PBS, harvested by scraping and centrifuged for 
2 min at 1000  g. The supernatant was removed, and the cell pellet was resuspended in 400 L 
of 50 mM Tris-HCl (pH 7.4) and 250 mM sucrose buffer. To lyse cells, cells were passed 
through a 30-gauge needle 15 times. The cell debris was pelleted by centrifugation at 600  g for 
5 min, and the supernatant was centrifuged at 100,000  g for 30 min to pellet cellular 
membranes. The membrane pellet was resuspended in 400 L of 50 mM Tris-HCl (pH 7.4) and 
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250 mM sucrose buffer and the protein concentration was determined as described in section 
3.6.1.  
DGAT assays were performed as described by Cases et al. (1998a). The assay measures 
the incorporation of [
14
C]oleoyl CoA into TG under apparent VMAX conditions using exogenous  
diacylglycerol. 50 g of membrane proteins were incubated with 20 mM MgCl2, and 100 mM 
Tris-HCl (pH 7.5) containing 125 g of BSA, 0.2 mM diacylglycerol and 25 M [14C]oleoyl 
CoA (18Ci/mol) (final volume, 0.2 mL). Reactions were carried out for 10 min at 37 C and 
terminated by adding 4 mL chloroform:methanol (2:1 v:v) and 0.8 mL water. After 
centrifugation at 956 × g for 5 min, the aqueous phase was removed. Lipids in the lower organic 
phase were dried under a stream of air and separated by thin layer chromatography (TLC) on 
channeled silica gel G60 TLC plates in hexane:ethyl ether:acetic acid (80:20:1 v:v:v). The bands 
corresponding to TG were scraped into tubes, and their radioactivity was measured by 
scintillation counting (Beckman Coulter, California, U.S.A.).  
 
3.5.2 In vitro ACAT Activity Assay 
 
ACAT assays measured the rate of incorporation of [
14
C]oleoyl CoA into cholesterol 
esters. Cholesterol was dissolved in acetone, which was allowed to evaporate, and Triton WR-
1339 as a 10% (w/v) solution in acetone was added to it at a ratio of 30:1 (w/w). 0.1 M K-
phosphate buffer (pH 7.4) was warmed to 60 C and then added to the cholesterol mixture with 
constant vortexing, and the organic layer of acetone was dried under a stream of air. The 
resultant transparent dispersion containing 200 g/L of cholesterol was immediately incubated 
with 120 g of total membrane proteins. 1 mM glutathione, 0.015 M BSA and 100 M 
[
14
C]oleoyl CoA were then added (final volume, 0.2 mL). The reaction was initiated by adding 
[
14
C]oleoyl CoA, carried out for 15 min at 37C and stopped by adding 4 mL 
chloroform:methanol (2:1 v:v) and 0.8 mL water. The incorporation of radioactivity into 
cholesterol esters was determined as described for DGAT assays.  
 
3.6 Immunoblot Analysis 
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3.6.1 Protein Determination 
 
The principle of the protein assay was to compare the absorbance maximum for 
Coomassie blue shifting from 465 nm to 595 nm by binding to protein. In a protein assay, 20 L 
of proteins was added to 100 L reagent A, and then mixed with 800 L reagent B (Bio-Rad). 
Samples were incubated at room temperature for 15 min, and then read at O.D.595 using a 
spectrophotometer (SmartSpec, Bio-Rad). A protein standard curve was prepared by using 
protein standards ranging from 0.2 mg/mL to 1.5 mg/mL. Next, the concentrations of protein 
standards were plotted against the corresponding absorbance resulting in a standard curve.  The 
concentration of the sample protein was thus determined. 
 
3.6.2 Preparation of Solubilized Membrane Proteins 
 
Transfected HEK-293T cells or COS7 cells were collected by centrifugation (86 × g, 2 
min), solubilized with 400 L 0.5% CHAPS in PBS in the presence of protease inhibitors and 
passed through a 30-gauge needle 15 times. Cell debris was removed by centrifugation at 16,873 
× g for 10 min at 4 C. The resulting supernatant contained solubilized membrane proteins. 
Protein content was determined as described in last section. 
 
3.6.3 SDS Polyacrylamide Gel Electrophoresis 
 
Protein samples were prepared by diluting 40 g of protein to 1 µg/µL in 5 SDS-PAGE 
sample buffer (250 mM Tris, pH 6.8, 10% SDS, 50% glycerol, 0.5% bromophenol blue, and 
25% -mercaptoethanol). When immunoblotting DGAT2, protein samples were heated to 100C 
for 5 min. When immunoblotting DGAT1, ACAT1 and FAR1, protein samples were incubated 
at 37C for 15 min to prevent aggregation. Denatured proteins were separated on a 10% SDS 
polyacrylamide gel consisting of 30% N,N’-methylene-bis-acrylamide (29:1), 375 mM Tris-HCl 
(pH 8.8), 0.1% SDS, 0.1% ammonium persulfate (APS), and 0.0004% N,N,N’,N’-
tetramethylethanediamine (TEMED) with a 5% stacking gel consisting acrylamide, 130 mM 
Tris-HCl (pH 6.8), 0.1% SDS, 0.1% APS and 0.001% TEMED. PageRuler prestained protein 
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ladder Plus was used to estimate protein size. Electrophoresis was carried out at 160 volts in 
running buffer containing 25 mM Tris-HCl, 192 mM glycine and 0.1% SDS. 
After separation by electrophoresis, proteins were transferred to a polyvinylidene fluoride 
membrane. The transferring process was carried out at 300 mA for 80-90 min in transfer buffer 
containing 62.5 mM boric acid, 5 N NaOH, pH 8. The membrane was blocked in 5% non-fat 
milk/ PBS-T (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 3 mM KH2PO4, 0.5% TWEEN

 
20, pH 7.4) for 1 h at room temperature with constant shaking. Blocking buffer was then 
changed with fresh buffer containing the appropriate primary antibody. The membrane was 
incubated at room temperature for another hour and then washed five times with fresh PBS-T for 
5 min each. Fresh PBS-T buffer containing secondary antibody linked to horseradish peroxidase 
was applied to the membrane for next hour. The membrane was then washed four times with 
PBS-T and one time with PBS for 5 min each. The protein-antibody complex on the membrane 
was next incubated with commercial chemiluminescent reagents for 5 min (SuperSignal

 West 
Pico Chemiluminescent Substrate) or home-made chemiluminescent reagents (250 mM luminol, 
40 mM coumaric acid, 1 M Tris-HCl pH 8.5 and 0.03% hydrogen peroxide [final volume: 20 
mL]) for 1 min and then exposed to film. The list of antibodies is in Table 3.2. 
 
3.7 Lipid Analysis 
 
3.7.1 Lipid Composition by Charring of TLC plates 
 
Cell lysates containing 750 g protein were diluted to a final volume of 1 mL with water. 
4 mL chloroform:methanol (2:1 v:v) was added, vortexed for 30 sec and the mixture was then 
centrifuged at 956 ×g for 5 min. The upper aqueous phase was removed and the organic phase 
was dried under a stream of air. Samples were resuspended in 60 L of chloroform:methanol 
(2:1 v:v) and applied to a TLC plate. Lipids were separating using the solvent system 
hexane:ethyl ether:acetic acid (80:20:1 v:v:v). The TLC plate was then air-dried, placed in a 
solution containing 10% cupric sulphate (w/v) and 8% phosphoric acid for 20 sec. The TLC plate 
was heated in an oven at 180C for ~7 min until lipids were visible. Lipid levels were quantified 
by densitometry and were linear within the range of our assay. Densities were determined using 
ImageJ software (National Institutes of Health). 
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3.7.2 Triacylglycerol Synthesis in Intact Cells 
 
Triacylglycerol synthesis in intact cells was determined by measuring the incorporation 
of [
3
H]glycerol into TG. HEK-293T cells were incubated with 10 Ci [3H]glycerol and 0.5 mM 
oleic acid in growth medium for 6 h. Lipids were extracted from cell lysates and separated as 
described in Section 3.7.1. Bands corresponding to TG were scraped from the TLC plate and the 
incorporation of radioactivity into [
3
H]TG was determined by liquid scintillation counting. 
 
3.8 Immunoprecipitation of DGAT1 
 
HEK-293T cells were lysed with 0.5% CHAPS in PBS by passing cells through a 30-
gauge needle 15 times. The cell debris was pelleted by centrifugation at 600  g for 5 min, and 
the supernatant was centrifuged at 100,000  g for 30 min at 4C to pellet cellular membranes. 
Resultant cell pellets were resuspended in 400 L of 0.5% CHAPS in PBS and pre-cleared by 
incubation with 50 L Protein A immobilized on Sepharose beads for 1 h at 4C while rotating 
to minimize non-specific binding. Protein A Sepharose beads were prepared according to 
manufacturer’s direction. Pre-cleared cell lysates was incubated with monoclonal Anti-FLAG 
M2 agarose beads (Sigma-Aldrich) for 2 h at 4C while rotating, and washed with 0.5% CHAPS 
in PBS for five times. Each washing used 1 mL buffer for 5 min, and proteins conjugated to 
antibodies on beads were pelleted by centrifugation for 1 min at 16,873 × g. Samples were eluted 
by 3  FLAG® Peptide (Sigma-Aldrich), 3 L of which were incubated with proteins derived 
from one plate. The immunoprecipitates were stored at -80C, if not used immediately. 
 
3.9 Mass Spectrometry and Identification of DGAT1 Interacting Proteins 
 
Immunoprecipitates were subjected to SDS-PAGE and stained with Coomassie blue to 
visualize immunoprecipitated proteins. Bands corresponding to DGAT1 as well as the 
compartment bands in untransfected cells were excised and sent for analysis by tandem mass 
spectrometry (service provided by Plant Biotechnology Institute, Saskatoon, SK). The obtained 
data were searched against both NCBInr 04012010 and Swiss Prot 57.15 databases (Taxonomy: 
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Homo sapiens). Proteins were predicted by the Mascot search engine, and the result was the 
probability indicating the match of the spectrum to a protein.  
  
35 
4. RESULTS 
 
 
4.1 Identification of DGAT1-Interacting Proteins 
 
Triacylglycerols are synthesized by DGAT enzymes at the ER and stored in cytosolic 
lipid droplets. Cholesterol esters are synthesized at the ER by ACAT and stored in lipid droplets 
as well. However, the formation of lipid droplets is a poorly understood process. It is also 
unclear how TG and cholesterol esters produced by DGAT enzymes and ACAT enzymes at the 
ER are incorporated into lipid droplets. Since almost all cellular processes require protein-protein 
interactions, DGAT1 may also have protein partners that facilitate TG synthesis and its storage 
into lipid droplets. To identify DGAT1-interacting proteins, we used co-immunoprecipitation in 
conjunction with mass spectrometry. 
Co-immunoprecipitation is a technique routinely utilized to identify protein-protein 
interactions in an unbiased manner. Proteins are precipitated out of the solution using a specific 
antibody that recognizes a bait protein. For the following experiments, DGAT1 containing a 
FLAG epitope at its N-terminus was expressed in HEK-293T cells and was immunoprecipitated 
using an anti-FLAG antibody. Proteins bound to DGAT1 should be present in the 
immunoprecipitates and their identities can be determined by mass spectrometry. One of the 
limitations of co-immunoprecipitation is that weakly interacting proteins can dissociate during 
experimental manipulations. The other limitation of this approach is that complex protein 
mixtures make it difficult to conclude that two interacting proteins bind each other directly 
(Masters, 2004; Anderson, 1998). 
 
4.1.1 Immunoprecipitation of DGAT1 
 
HEK-293T cells were chosen to overexpress DGAT1. FLAG-tagged murine DGAT1 
(FL-DGAT1) cDNA was transiently transfected into HEK-293T cells. DGAT1 is approximately 
55 kDa, and in SDS-PAGE it usually migrates near 50 kDa. The expression of DGAT1 was 
confirmed by immunoblotting with anti-FLAG (Figure 4.1A). Protein extracts from 
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untransfected HEK-293T cells and HEK-293T cells expressing FL-DGAT1 were then 
solubilized with 0.5% CHAPS and pre-cleared by incubation with protein A Sepharose for 30 
min on a rotating platform to minimize non-specific binding. DGAT1 was immunoprecipitated 
with anti-FLAG and detected with anti-FLAG antibodies by immunoblot analysis (Figure 4.1B). 
When the immunoprecipitates were stained with Coomassie Blue, several protein bands were 
detected in the DGAT1 immunoprecipitates that were absent in the immunoprecipitates from 
untransfected cells (Figure 4.1C). These proteins were excised and identified by mass 
spectrometry. 
 
4.1.2 Protein Identification by Mass Spectrometry 
 
Mass spectrometry is used to analyze the mass-to-charge ratio of unknown charged 
particles or peptides. Immunoprecipitates were separated by SDS-PAGE and stained with 
Coomassie Blue. Protein bands visualized in DGAT1 immunoprecipitates were designated P6b, 
P7b and P8b and their counterparts in untransfected immunoprecipitates were designated P6a, 
P7a and P8a (Figure 4.1C). These bands in the gels were excised and sent to the mass 
spectrometry core facility at NRC-PBI (National Research Council Plant Biotechnology 
Institute) for identification of candidate interacting proteins of DGAT1. 
 
      
 
  
      
  
 
 
 
 
A. B. 
kDa 
C. 
Figure 4.1. Immunoprecipitation of DGAT1 expressed in HEK-293T Cells. (A) By 
immunoblot analysis, cell lysates from HEK-293T transfected with FL-DGAT1 and 
untransfected cells were immunoblotted with anti-FLAG. (B) Immunoprecipitates from HEK-
293T cells expressing FL-DGAT1 and untransfected cells were immunoblotted with anti-FLAG. 
DGAT1 is indicated by the arrow. (C) Same IP samples of DGAT1 and untransfected cells were 
stained with Coomassie Blue. Bands labeled as P6b, P7b and P8b in D1 samples and bands 
labeled as P6a, P7a and P8a in UT samples were excised and sent for Mass spectrometry. D1, 
DGAT1. UT, untransfected cells. IP, immunoprecipitation. 
Anti-FLAG Anti-FLAG Coomassie Blue 
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Proteins were identified by comparison to databases of NCBInr 04012010 and SwissProt 
57.15, and those both present in immunoprecipitates from DGAT1 and untransfected cells were 
considered to be a result of non-specific binding. Candidate binding proteins are listed in Table 
4.1. 
 
Table 4.1: List of Candidate Binding Proteins from Mass Spectrometry 
 
 Abbr. Full Name Function Description/ Peptides 
P6 ACAT1 Acyl-CoA:cholesterol 
acyltransferase 
Cholesterol ester synthesis (Lee et al., 1998). 
Peptides matched: “KESLETPSNGRI”, 
“KEVGSHFDDFVTNLIEKS”. 
 PTSS2 Phosphatidylserine synthase 2 
 
PS synthesis (Bergo et al., 2002). Peptide 
matched: “RDAGGPRPESPVPAGRA”. 
 APMAP Adipocyte plasma membrane-
associated protein 
A transcript required for adipogenesis 
(Bogner-Strauss et al., 2010). Peptides 
matched: “KLLLSSETPIEGKN”, “KGLFE-
VNPWKR”. 
P7 SPTC1 Serine palmitoyltransferase 1 Sphingolipid synthesis (Hanada, 2003). 
Peptide matched: “RVVVTVEQTEEELER-
A”, “KTEEAIIYSYGFATIASAIPAYSKR”. 
 LPCAT1 Lysophosphatidylcholine 
acyltransferase 1 
Phosphatidylcholine synthesis (Nakanishi et 
al., 2006) Peptide matched: “KTALGVAE-
LTVTDLFRA”. 
 FAR1 Fatty acyl-CoA reductase 1 Wax biosynthesis (Cheng and Russell, 
2004a; Cheng and Russell, 2004b). Peptide 
matched: “KAPAFLYDIYLRM”. 
 DHCR24 24-dehydrocholesterol 
reductase 
Cholesterol biosynthesis (Waterham et al., 
2001). Peptide matched: “REGLEYIPLRH”. 
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4.2 Interaction of DGAT1 and ACAT1 
 
4.2.1 DGAT1 Interacts With ACAT1 
 
We first chose to investigate the role of ACAT1 as a DGAT1 interacting protein since 
ACAT1 also uses fatty acyl-CoA as a substrate and ACAT1 is related to DGAT1. This common 
feature of DGAT1 and ACAT1 might enable them to accept fatty acyl-CoA from possibly the 
same acyl donor carrier protein and thus DGAT1 and ACAT1 could interact. Since DGAT2 
catalyzes TG synthesis, we were also interested if ACAT1 interacted with DGAT2. FL-DGAT1 
and FLAG-tagged DGAT2 (FL-DGAT2) were transfected into HEK-293T cells. We chose 
HEK-293T cells as the have the fundamental pathway for TG biosynthesis present. FL-DGAT1 
and FL-DGAT2 were then immunoprecipitated using anti-FLAG coupled to agarose. 
Immunoprecipitates were immunoblotted with anti-FLAG to confirm the presence of FL-
DGAT1 and FL-DGAT2 (Figure 4.2A). To verify whether ACAT1 could be co-
immunoprecipitated with DGAT1 and DGAT2, we probed FL-DGAT1 and FL-DGAT2 
immunoprecipitates with an ACAT1 antibody. ACAT1 (~50kDa) was present in FL-DGAT1 
immunoprecipitates, but absent in FL-DGAT2 and untransfected immunoprecipitates (Figure 
4.2B). This data suggested that ACAT1 interacted with DGAT1, but not DGAT2. To verify that 
the visualized ACAT1 band was not caused by a non-specific reaction between the secondary 
antibody and ACAT1, the immunoprecipitates were blotted with secondary antibody only 
(Figure 4.2C). The ACAT1 band was not detected in the absence of ACAT1 antibody. Combined 
with the result of mass spectrometry, this experiment confirmed that ACAT1 could interact with 
DGAT1, but not DGAT2. 
 
4.2.2 Effect of ACAT1 Knockdown on DGAT Activity and TG Synthesis 
 
We next determined whether the interaction of DGAT1 and ACAT1 could influence 
DGAT1 function and TG synthesis. Since DGAT1 and ACAT1 share a common substrate, fatty 
acyl-CoA, we hypothesized that ACAT1 competed with DGAT1 for this substrate and the 
knockdown of ACAT1 could increase TG synthesis. To address this question, we suppressed  
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ACAT1 expression with two different small interfering RNA (siRNA) oligonucleotides, 5-
siRNA and 7-siRNA, and comparing siRNA-transfected cells to untransfected cells. Immunoblot 
analysis showed that ACAT1 was successfully knocked down by either 5-siRNA or 7-siRNA 
(Figure 4.3). We next examined the consequences of ACAT1 knockdown on DGAT activity and 
TG synthesis. Unexpectedly, in vitro DGAT activity was decreased when ACAT1 was knocked 
down with 5-siRNA (Figure 4.4). No consistent decrease in DGAT activity was observed for 7-
siRNA. Therefore, the interaction of DGAT1 and ACAT1 may stabilize DGAT1, and the 
disruption of it could increase DGAT1 degradation leading to decreased DGAT activity. We also 
examined the effect of ACAT1 knockdown on TG synthesis in intact HEK-293T cells. The 
knockdown of ACAT1 was verified by immunoblot analysis (Figure 4.5). Lipids in HEK-293T 
cells were extracted, separated by TLC and visualized by charring. Oleic acid can stimulate TG 
synthesis in the cell. If ACAT1 knockdown affected TG synthesis, ACAT1-knockdown cells 
would not response to oleic acid supplementation as much as wild-type cells do and TG levels in 
Figure 4.2. DGAT1 and ACAT1 interact with each other. (A) Immunoprecipitates from 
HEK-293T cells expressing FL-DGAT1, FL-DGAT2 and untransfected cells were analyzed by 
immunoblot analysis using anti-FLAG. (B) Immunoprecipitates from HEK-293T cells 
expressing FL-DGAT1, FL-DGAT2 and untransfected cells were analyzed by immunoblot 
analysis using anti-ACAT1. The ACAT1 band was indicated with a white arrow. (C) Same IP 
samples from the last experiment were immunoblotted with secondary antibody only. UT, 
untransfected cells. IP, immunoprecipitates. 
A. B. C. 
Anti-FLAG 
 
Anti-ACAT1 
 
Secondary antibody only 
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ACAT1-knockdown cells would be much lower in the presence of oleic acid compared to wild-
type cells. 
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Figure 4.3. ACAT1 knockdown using siRNAs. Immunoblot analysis for ACAT1 expression 
in cell lysates from HEK-293T cells transfected with ACAT1 siRNAs and untransfected cells. 
5-, 7-siRNA, different ACAT1-specific siRNA oligonucleotides. UT, untransfected cells. 
Figure 4.4. The effect of ACAT1 knockdown on DGAT activity. DGAT activity analysis in 
cell lysates from HEK-293T cells transfected with ACAT1 siRNAs and untransfected cells. 5-, 
7-siRNA, different ACAT1-specific siRNA oligonucleotides. UT, untransfected cells. n=2 
samples of each group. The experiment was repeated with similar results. 
Anti-ACAT1 
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As shown, cholesterol ester levels decreased due to ACAT1 knockdown in both the 
presence and absence of added oleic acid (Figure 4.6A). In the absence of oleic acid, TG levels 
declined in all siRNA-transfected samples. In the presence of oleic acid, neither 7-siRNA nor 5-
siRNA could significantly decrease TG levels. This result was probably due to endogenous 
DGAT2 using oleic acid for TG synthesis. The fact that ACAT1 knockdown decreased TG level 
in the absence of oleic acid suggested that TG synthesis was dependent on the interaction of 
DGAT1 and ACAT1. 
 
4.2.3 DGAT1 Does Not Have ACAT Activity and ACAT1 Does Not Have DGAT Activity 
 
Previous studies have shown that DGAT1 does not have ACAT activity and ACAT1 
does not have DGAT activity (Cases et al., 1998a; Yen et al., 2005). Due to the finding that 
ACAT1 knockdown decreased not only cholesterol ester levels but also TG levels, it was 
necessary to confirm the former conclusions in our studies. HEK-293T cells were transfected 
with either DGAT1 or ACAT1. In DGAT activity assays, DGAT1-transfected cells showed 
increased DGAT activity, while ACAT1-transfected cells did not (Figure 4.7). ACAT activity 
assays showed that ACAT1 overexpression increased ACAT activity, whereas DGAT1 
overexpression did not. 
Figure 4.5. The silencing of ACAT1 in +/- oleic acid conditions. Immunoblot analysis for 
ACAT1 expression in cell lysates from untransfected cells and HEK-293T cells transfected with 
ACAT1 siRNAs in the presence or absence of 0.375mM oleic acid. OA, oleic acid. “+” and “-”, 
in presence or absence of oleic acid. 
 
Anti-ACAT1 
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Figure 4.6. Lipid profile of HEK-293T cells transfected with ACAT1-specific siRNA with 
+/- oleic acid. (A) Total lipids were extracted from untransfected cells and HEK-293T cells 
transfected with siRNAs in the presence or absence of 0.375mM oleic acid. Lipid extracts 
were analyzed by thin layer chromatography. (B) TG was quantified by densitometry using 
ImageJ and compared in chart. UT, untransfected cells. OA, oleic acid. n=3 samples for each 
group. The experiment was repeated with similar results. 
A. 
B. 
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4.2.4 Effect of ACAT1 and DGAT1 Overexpression on TG and Cholesterol Ester Synthesis 
 
If silencing ACAT1 could decrease TG levels in the absence of fatty acids, we 
hypothesized that ACAT1 overexpression would increase TG levels. To test this hypothesis, 
HEK-293T cells were transfected with the expression vector of ACAT1 and supplemented with 
oleic acid or cholesterol. The purpose of cholesterol treatment is that cholesterol activates 
ACAT1 and supplies substrates for cholesterol ester synthesis (Zhang et al., 2003). If the 
interaction between DGAT1 and ACAT1 could influence the synthesis of their respective 
products, we hypothesized that cholesterol-stimulating ACAT1 overexpression increased TG and 
cholesterol ester synthesis. ACAT1 overexpression was confirmed using anti-ACAT1 (Figure 
4.8A). In the presence and absence of oleic acid or cholesterol, ectopic ACAT1 expression 
increased both cholesterol ester and TG production, especially with the addition of cholesterol 
(Figure 4.8B and 4.8C). The reason why ACAT1 could increase TG synthesis was probably that 
ACAT1 overexpression up-regulated DGAT activity or the DGAT1 protein level that resulted in 
more functional ACAT1-DGAT1 complex forming, and thereby producing TG. This finding fur- 
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Figure 4.7. Acyltransferase activities of DGAT1 and ACAT1. DGAT and ACAT activity 
analysis in cell lysates from HEK-293T cells transfected with DGAT1 or ACAT1 and 
untransfected cells. n=3 samples for each group. The experiment was repeated with similar 
results. 
  
44 
 
                               
   
 
 
 
 
 
 
 
ther supported a cooperative the hypothesis of a relationship between ACAT1 and DGAT1. 
To better understand the results of how ACAT1 could increase TG synthesis under +/- 
oleic acid and cholesterol, we individually transfected ACAT1 or FL-DGAT1 in +/- cholesterol 
conditions and tested their effects on lipid synthesis. FL-DGAT1 and ACAT1 expression was 
confirmed by immunoblot analysis with anti-FLAG or anti-ACAT1, respectively (Figure 4.9A). 
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Figure 4.8. Lipid profile of HEK-293T cells overexpressing ACAT1 in +/- oleic acid and 
+/- cholesterol conditions. (A) Immunoblot analysis for ACAT1 expression in cell lysates 
from untransfected cells and HEK-293T cells transfected with ACAT1 in the presence or 
absence of 0.375mM oleic acid and 25 µg/mL cholesterol. (B) Total lipids were extracted from 
untransfected cells and HEK-293T cells transfected with ACAT1 in the presence or absence of 
oleic acid and cholesterol. Lipid extracts were analyzed by thin layer chromatography. (C) TG 
was quantified by densitometry using ImageJ. *, P<0.05, versus UT. OA, oleic acid. Ch, 
cholesterol. UT, untransfected cells. Error bars stand for standard error of the means. n=3 
samples for each group. The experiment was repeated with similar results. 
B. 
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Both overexpression of ACAT1 and FL-DGAT1 could increase cholesterol ester level in +/- 
cholesterol (Figure 4.9B and 4.9C). Furthermore, in +/- cholesterol, ACAT1-transfected cells 
produced more TGs than the control. 
Our explanation for these findings was that DGAT1 and ACAT1 assisted each other to 
synthesize TG and cholesterol esters, respectively. Since we have confirmed that DGAT1 and 
ACAT1 interact with each other, we propose that DGAT1 and ACAT1 interact as part of a lipid- 
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Figure 4.9. Lipid analysis on HEK-293T cells overexpressing DGAT1 and ACAT1 in +/- 
cholesterol conditions.  (A) Immunoblot analysis for FL-DGAT1 and ACAT1 expression in 
cell lysates from untransfected cells and HEK-293T cells transfected with FL-DGAT1 and 
ACAT1 in the presence or absence of 25 µg/mL cholesterol. (B) Total lipids were extracted 
from untransfected cells and HEK-293T cells transfected with FL-DGAT1 and ACAT1 in the 
presence or absence of cholesterol. Lipid extracts were analyzed by thin layer chromatography. 
(C) TG was quantified by densitometry using ImageJ. A1, ACAT1. D1, FL-DGAT1. UT, 
untransfected cells. -Ch, normal condition without cholesterol. +Ch, cholesterol treatment. n=3 
samples for each group. The experiment was repeated with similar results. 
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synthesizing complex, or DGAT1-ACAT1 protein complex, producing both TG and cholesterol 
esters. Either increasing the amount of DGAT1 or ACAT1 protein could lead to more DGAT1-
ACAT1 protein complex formation, and thus increase the product synthesis of both of them. This 
was why ACAT1 transfection increased TG synthesis. 
         
4.2.5 Identification of the Domain of DGAT1 that Interacts with ACAT1 
 
We next tried to identify which region of DGAT1 was responsible for interacting with 
ACAT1. The approach was to determine if ACAT1 could be co-immunoprecipitated with 
various DGAT1 mutants that had been generated from a previous study (McFie et al., 2010). 
DGAT1 and all DGAT1 mutants (Δ1-37, Δ38-84 and Δ1-85) had a FLAG tag in their N-
terminus (Figure 4.10A). FL-DGAT1 and the FL-DGAT1 mutants, Δ1-37, Δ38-84 and Δ1-85, 
were expressed in HEK-293T cells and immunoprecipitated with anti-FLAG. The 
immunoprecipitates were then immunoblotted with anti-FLAG and anti-ACAT1 antibodies. 
Immunoblot analysis with anti-FLAG confirmed that FL-DGAT1 and the three mutants were 
successfully immunoprecipitated (Figure 4.10B). However, ACAT1 was also detected in the 
immunoprecipitates of all three FL-DGAT1 mutants, indicating that DGAT1 did not interact 
with ACAT via its N-terminal domain (Figure 4.10C). 
 
4.3 DGAT1 Does Not Interact with FAR1 
 
We next studied FAR1, another potential DGAT1 interacting protein identified by mass 
spectrometry.  HEK-293T cells were transfected with FL-DGAT1, Myc-FAR1 and FL-DGAT1 
and Myc-FAR1 together, respectively. The expression of FL-DGAT1 and Myc-FAR1 was 
confirmed by immunoblotting cell lysates with anti-FLAG and anti-Myc (Figure 4.11A and B, 
lanes of cell lysates). Solubilized cell lysates containing FL-DGAT1 were incubated with anti-
FLAG and FL-DGAT1 was immunoprecipitated and immunoblotted by anti-FLAG (Figure 
4.11A, lanes of IP).  
  
47 
                 
 
                   
                    
 
 
 
 
 
However, for co-immunoprecipitation, Myc-FAR1 was shown present in 
immunoprecipitates from cells expressing only Myc-FAR1 as well as immunoprecipitates from 
cells co-expressing FL-DGAT1 and Myc-FAR1 (Figure 4.11B, lanes of IP). This result 
suggested that Myc-FAR1 was pulled down non-specifically. If DGAT1 interacted with FAR1, 
then Myc-FAR1 should be pulled down when co-expressed with FL-DGAT1. However, the 
Figure 4.10. Identification of the region of DGAT1 interacting with ACAT1. (A) A map of 
DGAT1 mutant proteins. (B) Full-length or deletion mutants of FL-DGAT1 expressed in HEK-
293T cells were immunoprecipitated and analyzed by immunoblotting using anti-FLAG. (C) 
Endogenous ACAT1 was immunoblotted by using anti-ACAT1 in FL-DGAT1 and FL-DGAT1 
mutants’ immunoprecipitates. 5X, sample loaded with 7.5µl IP elution. 1X, 1.5µl. 0.5X, 0.75µl. 
0.1X, 0.15µl. UT, untransfected cells. IP, immunoprecipitation. 
 
 
B. 
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Anti-ACAT1 
 
C. 
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result showed that the Myc-FAR1 level from Figure 4.11B did not increase significantly. 
Therefore, it appears that Myc-FAR1 was pulled down due to non-specific binding of FAR1 with 
anti-FLAG.  
                 
               
                           
 
 
 
 
Figure 4.11. DGAT1 and FAR1 do not interact. (A) Immunoblot analysis of DGAT1 
expression and immunoprecipitation from HEK-293T cells transfected with FL-DGAT1, Myc-
FAR1, FL-DGAT1 and Myc-FAR1 and P-FAR1. (B) Immunoblot analysis of FAR1 expression 
and immunoprecipitation was prepared in the same way as the last experiment. (C) The repeat of 
the experiment shown in Fig. 4.11B. UT, untransfected cells. FL-D1, FL-DGAT1. M-F1, Myc-
FAR1. FL-D1&M-F1, FL-DGAT1 and Myc-FAR1 co-transfection. P-F1, FAR1 without any 
epitope. UT, untransfected cells. IP, immunoprecipitation. 
A. 
B. 
C. 
Anti-FLAG 
 
Anti-Myc 
Anti-Myc 
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If DGAT1 and FAR1 indeed interacted, the result of co-immunoprecipitation shown 
should be like Figure 4.11C, in which Myc-FAR1 was present in co-transfection 
immunoprecipitates and absent in single-transfection immunoprecipitates. But the result in 
Figure 4.11C was not repeatable. Since DGAT1 is localized to the ER and FAR1 is present in 
peroxisome, it is unlikely that DGAT1 and FAR1 interact. 
 
4.4 Interaction of DGAT1 and DGAT2 
 
To determine if DGAT1 interacted with DGAT2, I co-expressed Myc-DGAT1 and FL-
DGAT2 in COS7 cells (African green monkey kidney cells). The reason that we switched the 
cell line from HEK-293T to COS7 was due to the promoter of FL-DGAT2, pEF-1α, was not 
active in HEK-293T cells. The co-expression of both FL-DGAT2 (predicted size: ~45 kDa, 
actual size: ~40 kDa) and Myc-DGAT1 was confirmed by immunoblot analysis with anti-FLAG 
and anti-Myc antibodies (Figure 4.12A and B). FL-DGAT2 was immunoprecipitated with anti-
FLAG, which was confirmed by immunoblot analysis (Figure 4.12C). Immunoprecipitates were 
then immunoblotted with anti-Myc (Figure 4.12D). Surprisingly, Myc-DGAT1 was present in 
the anti-FLAG immunoprecipitates, and suggested that DGAT1 could interact with DGAT2.  
 
4.4.1 Effect of DGAT1 and DGAT2 Interaction on Lipid Synthesis 
 
Based on our finding that DGAT1 and DGAT2 interacted, we hypothesized that DGAT1 
and DGAT2’s interaction could facilitate lipid synthesis. To test this, HEK-293T cells were used 
for the co-transfection of FL-DGAT1 and FL-DGAT2. The expression of FL-DGAT1 and FL-
DGAT2 was confirmed by probing with anti-FLAG, though it was not clear why less DGAT2 
was detected under boiled condition. One possibility is that some DGAT2 precipitated due to the 
boiling (Figure 4.13). Lipid synthesis was then compared among HEK-293T cells transfected 
with LacZ, FL-DGAT1, FL-DGAT2 and FL-DGAT1&FL-DGAT2 in presence or absence of 
oleic acid. 
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Lipids were extracted and separated by TLC (thin layer chromatography). TG levels in 
different conditions were converted to values and compared (Figure 4.14). FL-DGAT2-
transfected cells appeared to synthesize more TGs than untransfected, FL-DGAT1 and LacZ-
transfected cells in +/- oleic acid conditions. However, TG levels appeared less in cells co-
expressing FL-DGAT1 and FL-DGAT2 compared to single DGAT-transfected cells. This result 
indicates that co-expression of DGAT1 and DGAT2 does not have an additive effect on TG 
synthesis in HEK-293T cells, possibly because DGAT1 and DGAT2 were competing for the 
same pool of substrates. 
Figure 4.12. DGAT1 and DGAT2 interact. Immunoblot analysis for COS7 cells transfected 
with pBud vector containing both Myc-DGAT1 and FL-DGAT2 and untransfected cells. (A) 
Cell lysates were separated by electrophoresis and immunoblotted with anti-FLAG antibody. (B) 
Same samples were separated and immunoblotted with anti-Myc antibody. (C) FL-DGAT2 was 
immunoprecipitated by using anti-FLAG, and FL-DGAT2 immunoprecipitates were 
immunoblotted with anti-FLAG. (D) FL-DGAT2 immunoprecipitates were re-immunoblotted 
with anti-Myc for immunoblot analysis. UT, untransfected cells. pBud, vector containing Myc-
DGAT1 and FL-DGAT2. IP, immunoprecipitation. 
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Figure 4.14. Lipid profile of HEK 293T cells overexpressing DGAT1, DGAT2 and 
DGAT1 and DGAT2. Total lipids were extracted from HEK-293T cells expressing LacZ, FL-
DGAT1, FL-DGAT2, FL-DGAT1 and FL-DGAT2 and untransfected cells. Lipid extracts were 
analyzed by TLC plate with hexane/ethyl ether/acetic acid (80:20:1). TG was quantified by 
densitometry using ImageJ. +OA, oleic acid treatment. D1+D2, FL-DGAT1 and FL-DGAT2 
co-transfection. n=1 sample for each group.  
Figure 4.13. Co-expression of FL-DGAT1 and FL-DGAT2 in HEK-293T cells. HEK-293T 
cells were transiently transfected with LacZ, FL-DGAT1 and/or FL-DGAT2. FL-DGAT1 was 
prepared under 37°C (to prevent aggregation) and 100°C (as a control). FL-DGAT2 were 
prepared under 100°C (to prevent aggregation) and 37°C (as a control). They were analyzed by 
immunoblotting using anti-FLAG antibody. LZ, LacZ transfection. D1/D2, FL-DGAT1 and FL-
DGAT2 co-transfection. 
kDa 
Anti-FLAG 
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5. DISCUSSION 
 
In previous studies, two DGAT2-interacting proteins have been identified, SCD1 and 
glycerol phosphate acyl-CoA acyltransferase, GPAT8 (Man et al., 2006; Gidda et al., 2011). In 
this study, we identified two proteins that interacted with DGAT1 — DGAT2 and ACAT1. We 
showed that the co-expression of DGAT1 and DGAT2 did not have a synergistic effect on TG 
synthesis. We also found that knockdown or overexpression of ACAT1 could decrease or 
increase TG and cholesterol ester synthesis, respectively. 
 
5.1 Different Functional Roles of DGAT1 and DGAT2 
 
We demonstrated that murine DGAT1 could interact with murine DGAT2. Combined 
with the topological models of DGAT1 and DGAT2 shown in Fig. 2.5 and Fig.2.6, it is possible 
that the N-terminus of DGAT1 interacts with C-terminus of DGAT2 as both of these regions are 
exposed to the cytoplasmic side of the ER. However, it should be noted that in some organisms 
this interaction may not happen since it has been reported that tung tree DGAT1 and DGAT2 
showed distinct, non-overlapping subcellular locations in the ER of tobacco BY-2 cells (Shockey 
et al., 2006). Therefore, if tung tree DGAT1 and DGAT2 distribute separately, it is unlikely that 
they interact with each other. 
We expected that the co-expression of DGAT1 and DGAT2 would increase TG 
synthesis, since DGAT1 or DGAT2 overexpression did. But our experiments showed that the co-
expression of DGAT1 and DGAT2 did not increase TG synthesis. It seemed that the interaction 
of DGAT1 and DGAT2 disrupted TG synthesis. One possible explanation was that DGAT1 and 
DGAT2 compete for the same pool of substrates, decreasing the substrate availability for each 
enzyme. Interestingly, DGAT2’s active site is oriented towards the cytosol and DGAT1’s is 
oriented in the ER lumen (Stone et al., 2006; Joyce et al., 2000). Therefore, fatty acyl moieties in 
the cytosol have to come across the ER membrane to access the active site of DGAT1.  
Perhaps DGAT1 and DGAT2 are able to regulate the enzyme activities of each other as 
well. For instance, DGAT1 may be able to inactivate DGAT2. When DGAT1 is up-regulated, 
DGAT1 could suppress the activity of DGAT2. On the contrary, when DGAT2 was up-
regulated, it could inactivate DGAT1. This might be an effective measure to control lipid 
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metabolism and meet different physiological needs. When under stress or fasting, TGs from the 
liver are incorporated into the VLDL with assistance from DGAT1 for secretion. Although the 
role of DGAT1 on VLDL assembly is still controversial, it is logical that DGAT1 is more 
capable for re-esterifying and incorporating hydrolyzed TGs into the VLDL than DGAT2, as it 
possesses both MGAT and DGAT activities. Also, the active site of DGAT1 is in the ER lumen 
where VLDLs are assembled. Hence, if DGAT1 prevailed as a response to fasting, it could 
inactivate and prevent DGAT2 from packaging TGs back into cytosolic lipid droplets for 
storage. On the contrary, DGAT2 could be responsible for de novo TG synthesis and TG storage. 
The active site of DGAT2 is oriented towards the cytosol where lipid droplets distributed. This 
mechanism might be pivotal for adipose tissue to be able to store lipids. Taken together, it is 
reasonable that DGAT1 and DGAT2 could regulate each other to serve different physiological 
functions. 
 
5.2 DGAT1 and ACAT1 May Be in the Same Protein Complex 
 
We also found that DGAT1 interacted with ACAT1. Before further discussing what this 
interaction might imply, a brief introduction on ACAT enzymes would be helpful. 
Two ACAT genes have been identified, ACAT1 and ACAT2 (Chang et al., 1993; 
Anderson et al., 1998; Cases et al., 1998b; Oelkers et al., 1998). ACAT enzymes are integral 
membrane proteins that catalyze the synthesis of cholesterol ester from cholesterol and fatty 
acids (Lin et al., 1999; Joyce et al., 2000). ACAT1 is present in the ER and contains nine 
transmembrane domains, with its N-termini facing the cytosol and C-termini in the ER lumen 
(Guo et al., 2005). ACAT2 also resides in ER and contains two transmembrane domains, with 
both of its N- and C-terminus facing the ER lumen (Lin et al., 2003). ACAT1 and ACAT2 share 
a high degree of homology (Anderson et al., 1998). Despite having so many similarities, ACAT 
enzymes are suggested to have different functions. In African green monkeys, ACAT1 is 
expressed ubiquitously while ACAT2 is expressed mainly in the liver and small intestine (Lee et 
al., 2000). In humans, ACAT1 accounts for most of the ACAT activity in the liver, while 
ACAT2 is expressed in a high level in the small intestine (Chang et al., 1998). ACAT1
-/-
 mice 
exhibited attenuated atherosclerosis but had cutaneous xanthomatosis and hyperlipidemia (Yagu 
et al., 2000). In contrast, ACAT2
-/-
 mice showed reduced dietary cholesterol absorption with a 
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cholesterol-fed diet (Repa et al., 2004). These functional studies suggested that ACAT1 was 
involved in intracellular cholesterol homeostasis, whereas ACAT2 was involved in dietary 
cholesterol absorption and redistribution. In addition, DGAT1, ACAT1 and ACAT2 are closely 
related and in the same gene family. DGAT1 and ACAT1 share 15-20% identity and both of 
them could form dimers and tetramers (ACAT1 could also form hetero-oligomers) (Hofmann, 
2000; Yu et al., 2002b; Yu et al., 1999; Kawasaki et al., 1998). DGAT1 and ACAT1 both have 
active sites facing the cytosolic side of the ER (Joyce et al., 2000). 
Our experiments demonstrated that disruption of ACAT1 gene expression with siRNA 
oligonucleotides decreased both cholesterol ester and TG synthesis in HEK-293T cells. This 
result agreed with previous in vivo studies that showed that ACAT1 deficient mice had decreased 
cholesterol ester and TG synthesis in the liver (Fazio et al., 2001; Meiner et al., 1996; Meiner et 
al., 1998). Moreover, the overexpression of ACAT1 in HEK-293T cells increased both 
cholesterol ester and TG levels. Why does ACAT1 knockdown or overexpression influence TG 
synthesis, as ACAT1 has no DGAT activity and DGAT1 lacks ACAT activity? We favor a 
model where ACAT1 and DGAT1 interact as part of a lipid-synthesizing complex producing 
both TG and cholesterol esters. When ACAT1 is overexpressed, more functional ACAT1-
DGAT1 protein complexes are generated, which results in up-regulated cholesterol ester and TG 
levels. On the other hand, DGAT1 could also affect cholesterol ester synthesis. DGAT1 deficient 
mice exhibited decreased cholesterol ester levels in the liver and other tissues (Chen et al., 
2002c; Streeper et al., 2006). In mouse macrophages lacking DGAT1, sterol ester levels were 
reduced (Harris et al., 2011). Our experiment showed that the overexpression of DGAT1 
increased cholesterol ester synthesis. Therefore, these results further support the concept that 
ACAT1 and DGAT1 interact as part of a lipid-synthesizing complex. If DGAT1 and ACAT1 
could be attached with different fluorescent tags, the condition of their co-localization could be 
detected. Combination of the usage of compartment markers for the ER or lipid droplets would 
further reveal their distribution and how their interaction affects their distribution. 
Perhaps, the interaction of DGAT1 and ACAT1 and its effects can help us understand 
VLDL secretion in the perspective of a DGAT1-ACAT1 protein complex. It is well documented 
that ACAT1 overexpression increases plasma VLDL levels, and ACAT inhibitors decrease 
plasma VLDL levels (Liang et al., 2004; Taghibiglou et al., 2001; Leon et al., 2005; Burnett et 
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al., 1999). Other studies showed that long-term (12 days) overexpression of human DGAT1 in 
hepatoma cells or in mice could increase the secretion of VLDL (Yamazaki et al., 2005; Millar et 
al., 2006). But, DGAT1 deficiency in mice did not affect VLDL secretion, and macrophages 
deficient in both DGAT enzymes could form lipid droplets with cholesterol-rich lipoproteins 
(Harris et al., 2011; Liu et al., 2008). Taken together, we speculate that an ACAT1-DGAT1 
protein complex promotes VLDL synthesis and secretion. In addition, mass spectrometry of 
DGAT1 immunoprecipitates revealed a protein capable of reducing cholesterol from its oxidized 
form, 24-dehydrocholesterol reductase (DLCR) (Waterham et al., 2001). This suggested that 
ACAT1 also had the ability to associate with other proteins, and thus the role of ACAT1 in the 
complex was an important one. 
Unfortunately, we could not identify the interacting regions between DGAT1 and 
ACAT1. Using DGAT1 mutants, we only found that the N-terminus of DGAT1 was not 
responsible for its interaction with ACAT1. Thus, a region in the C-terminus of DGAT1 likely 
interacts with ACAT1. 
 
5.3 Role of FAR1 
 
By mass spectrometry, fatty acyl-CoA reductase 1 (FAR1) was identified as a potential 
DGAT1-interacting protein. Unfortunately, we could not confirm this interaction. FAR1 reduces 
fatty acyl-CoA to synthesize fatty alcohol (Cheng and Russell, 2004a; Cheng and Russell, 
2004b). It localizes to the peroxisome and prefers fatty acids with 16 or 18 carbons, which are 
the preferred substrates of DGAT1. In mammals, FAR1 is ubiquitously expressed. High FAR1 
mRNA levels are found in organs synthesizing wax esters and ether lipids, such as the brain and 
sebaceous glands (Wanders and Waterham, 2006). Specifically, as DGAT1 possesses wax 
synthase activity and FAR1 is capable of supplying fatty alcohol, we hypothesized that they 
might interact. However, our experiments showed that although FAR1 was a potential binding 
partner of DGAT1 as identified by mass spectrometry, FAR1 could not be co-
immunoprecipitated with DGAT1 indicating that these two proteins do not interact. Moreover, 
DGAT1 and FAR1 are present in different subcellular compartments. DGAT1 resides in the ER 
and FAR1 is localized to peroxisomes (Stone et al., 2009; Cheng and Russell, 2004a). 
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5.4 TG Synthetase Complex 
 
In order to increase local substrate concentration and allowing serial biochemical 
reactions to proceed efficiently, a protein complex is preferred for catalyzing a series of 
reactions. A TG-synthetase complex is proposed in Figure 5.1. 
While DGAT1 and DGAT2 interact and may appear in the same TG-synthetase complex, 
it is possible that DGAT1 and DGAT2 could perform different functional roles. I propose that 
the two DGAT enzymes are able to group with different protein partners in a nonsimultaneous 
manner. Particularly, when DGAT1 associates with its protein partners, DGAT2 cannot form a 
complex with other protein partners except for DGAT1. On the other hand, when DGAT2 is 
grouped with its protein partners, DGAT1 cannot complex with other protein partners except for 
DGAT2. Therefore, there may be heterogeneous TG-synthetase complexes associating with 
different proteins to perform distinct functions. DGAT1 would associate with enzymes 
responsible for lipid re-esterification and redistribution, such as ACAT1 and MGAT. One TG-
synthetase complex found in the rat intestinal cells possessed acyl-CoA ligase (ACL), AAT, 
MGAT and DGAT activities (Lehner and Kuksis, 1995). We suspect that the core DGAT 
enzyme involved in this complex was DGAT1. Firstly, DGAT1 possesses MGAT activity and is 
more dependent on dietary diacylglycerol from hydrolyzed fats (Yen et al., 2005). Also, in the 
same study, one protein associated with AAT was 54kDa, which is about the size of DGAT1. 
Third, according to the fact that DGAT1 deficient mice exhibit delayed chylomicron secretion 
compared to wild-type mice, DGAT2 was suggested to interact with another diacylglycerol 
transacylase instead of MGAT in this case (Buhman et al., 2002).  
In contrast, DGAT2 is responsible for bulk TG synthesis. Thus, it is likely complexed 
with proteins involved in de novo TG biosynthetic pathway such as GPAT, LPAT and PAP. A 
cytosolic TG-synthetase complex was demonstrated in Rhodotorula glutinis (Gangar et al., 
2001). It contained LPAT, PAP, DGAT, acyl-acyl carrier protein synthetase (AACS) and an acyl 
carrier protein. The main enzymes in de novo TG synthetic pathway were present, and we 
speculate that DGAT2 (specifically, its ortholog in yeast) was the core in this protein complex. 
DGAT2 appears to use endogenous fatty acids and associated proteins supplying them, such as 
SCD1. Therefore, the TG-synthetase complex with high ability for de novo TG synthesis is likely 
to employ DGAT2 as the core protein to perform its function. 
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Figure 5.1. Proposed TG synthetase complexes. DGAT1 and DGAT2 transiently group with 
different protein partners and determine the functions of the complex. The function of DGAT1 
complex might be involved in lipid redistribution with using exogenous (dietary) lipids. DGAT2 
complex might mainly store lipids using both exogenous and endogenous lipids. Two pools of 
lipids could be transferred from each other. The question mark refers to the proposed interaction 
and other unknown proteins that may associate with DGAT enzymes. DLCR, 24-
dehydrocholesterol reductase. ACL, acyl-CoA ligase. AACS, acyl-acyl carrier protein synthetase. 
APMAP, adipocyte plasma membrane-associated protein. AAT, acyl-acyl transferase. SPTC1, 
serine palmitoyltransferase 1. PTSS2, Phosphatidylserine synthase 2. LPCAT1, 
lysophosphatidylcholine acyltransferase 1. SCD1, stearoyl-CoA desaturase 1. GPAT8, glycerol 
phosphate acyl-CoA transferase 8. LPAT, lysophosphatidate acyl transferase. PAP, phosphatidate 
phosphatase. 
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TG-synthetase complex might determine the direction of lipid synthesis, such as from 
diacylglycerol to TGs, or from diacylglycerol to phospholipids. The down-regulation of DGAT 
enzymes, which would suppress the TG-synthetase complex, could promote the lipid efflux from 
diacylglycerol to phospholipids instead of TG. During cell division, DGAT1 and DGAT2 mRNA 
levels were suppressed by the MEK-ERK pathway, which was responsible for decreasing the 
secretion of VLDL (TG-rich lipoprotein) and TG synthesis (Tsai et al., 2007; Wang et al., 2010). 
This implied that under cell division, diacylglycerol were used for the synthesis of phospholipids 
instead of TG. On the other hand, the up-regulation of DGAT enzymes that resulted in more TG-
synthetase complexes were likely capable of shifting the flux of lipids from phospholipids to TG. 
Thirdly, in the TG-synthetase complex, DGAT-interacting proteins might provide signals 
for different cellular activities. We speculated that two proteins revealed from mass spectrometry 
could perform this function. A plasma membrane-associated protein (APMAP) was shown to 
interact with DGAT1. Current studies show that APMAP localizes to the ER in preadipocytes 
and translocates to the plasma membrane during adipogenesis (Bogner-Strauss et al., 2010). The 
silencing of APMAP can impair adipogenesis. Enforced overexpression of APMAP, however, 
cannot initiate the translocation of APMAP to plasma membrane in preadipocytes. Therefore, the 
translocation of APMAP may need the up-regulation of DGAT1, as does DGAT1 during 
adipogenesis. If enforced co-expression of DGAT1 and APMAP in preadipocytes could promote 
APMAP translocate to the plasma membrane, this potential interaction of DGAT1 and APMAP 
could be indirectly identified and important for adipogenesis. In addition, DGAT1 could possibly 
also interact with serine palmitoyltransferase 1, which synthesizes sphinganine, a precursor of 
ceramide synthesis. The latter can be attached onto sugar molecules to transmit various cell-
signals, such as differentiation, proliferation or apoptosis. Thus, the potential interaction between 
DGAT1 and serine palmitoyltransferase 1 may serve to provide different cell signals. 
Furthermore, from mass spectrometry of DGAT1 immunoprecipitates, we observed 
phosphatidylserine synthase 2 (PTSS2), serine palmitoyltransferase 1 (SPTC1) and 
lysophosphatidylcholine acyltransferase 1 (LPCAT1) (Table 3). All these proteins localize to the 
ER as DGAT1 does, which increases the chances for them to interact with DGAT1 and affect the 
balance of TG and their product formation. Specifically, LPCAT1 could synthesize 
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phosphatidylcholine that forms the lipid membrane layer. LPCAT has been reported to surround 
the lipid droplets and is hypothesized to assist the expansion of the lipid droplet membrane 
independent of an ER connection (Moessinger et al., 2011). TG-synthetase likely interacts with 
LPCAT1 to incorporate TG into lipid droplets. If the co-immunoprecipitation of LPCAT1 could 
reveal DGAT1, it would help us further understand the formation of lipid droplets.  
 
5.5 Future Directions 
 
Our experiments have studied the relationship between DGAT1 and DGAT2 as well as 
DGAT1 and ACAT1. Further studies might include investigating the hypothesis that DGAT1 
and DGAT2 serve different functional roles. We are also interested in finding out other effects of 
DGAT1 and ACAT1’s interaction, and better understanding the biochemical significance of this 
interaction, such as VLDL formation. We could determine the possible interactions between 
DGAT1 and other lipid-synthesizing proteins, and explore the formation of lipid droplets and 
whether these possible interactions could divert the lipid synthesis direction. 
To determine whether DGAT1 and DGAT2 can regulate the activities of each other, we 
could identify interacting regions of DGAT1 with DGAT2 by constructing DGAT1 truncated 
mutants (without the C-terminus or middle region). Truncated DGAT1 mutants without 
interacting regions would be expected to be incapable of binding to DGAT2 and would not be 
co-immunoprecipitated. Thus interacting regions of DGAT1 and DGAT2 could be identified. 
We already found that the co-transfection of DGAT1 and DGAT2 could not increase TG 
synthesis. Therefore, DGAT1 might be able to regulate the enzyme activity of DGAT2. To 
verify this hypothesis, we could design mutant DGAT1 unable to associate with DGAT2 by 
deleting its DGAT2-interacting region, and the mutant DGAT1 would be co-transfected with 
normal DGAT2. If the co-transfection increased TG synthesis, it would suggest that mutant 
DGAT1 could no longer regulate, specifically inhibit, DGAT2 and thus TG synthesis increased. 
Further, the enzyme kinetics of DGAT2 could be determined when DGAT2 was co-transfected 
with mutant DGAT1 without DGAT activity constructed by site-directed mutagenesis. If 
DGAT2’s affinity for substrates decreased, the hypothesis is valid. It would further demonstrate 
that DGAT1 and DGAT2 had different functional roles in TG synthesis. 
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We have shown that DGAT1 and ACAT1 overexpression increases cholesterol ester and 
TG synthesis, respectively. Next we could identify the interacting regions residing in DGAT1 
and ACAT1 sequence, and this could provide information of DGAT1 and ACAT1’s effects on 
VLDL secretion. As reviewed, ACAT1 was positively related to plasma VLDL (Liang et al., 
2004; Wilcox et al., 1999; Burnett et al., 1997). In contrast, DGAT1 seemed only to facilitate 
VLDL secretion (Yamazaki et al., 2005; Millar et al., 2006; Liu et al., 2008). We could 
determine the interacting regions of DGAT1 and ACAT1 by designing truncated DGAT1 or 
ACAT1. After identifying the interacting region, mutant DGAT1 unable to interact with ACAT1 
could be used for co-expression with ACAT1. If the co-expression of mutant DGAT1 and 
normal ACAT1 did not increase plasma VLDL or the TG content of VLDL, it would suggest 
that DGAT1 could assist ACAT1 for VLDL secretion. In addition, obesity was shown associated 
with high plasma cholesterol levels. We could compare cholesterol ester and cholesterol levels 
between cells co-expressing DGAT1 mutant with ACAT1 and normal DGAT1 with ACAT1. If 
mutant DGAT1 and ACAT1 overexpression showed decreased cholesterol ester content in lipid 
droplet, it would suggest that the interaction of DGAT1 and ACAT1 is significant for cholesterol 
ester incorporation into lipid droplets. That would further imply that the interaction of DGAT1 
and ACAT1 is crucial for cholesterol ester storage and plasma cholesterol balance inside body. 
In addition, we could also determine the relationships between DGAT enzymes and 
proteins responsible for phospholipid and sphingolipid synthesis revealed by mass spectrometry 
of DGAT1 immunoprecipitates. Do these proteins compete for substrate (acyl moieties) with 
DGAT enzymes or DGAT enzymes utilize phospholipids as acyl donor to generate TG? On one 
hand, our experiment has demonstrated that DGAT1 and DGAT2 might compete for the same 
pools of substrates, which suggests that DGAT1-associating proteins could have a competing 
relationship with DGAT1. On the other hand, in yeast and plant a phospholipid acyltransferase 
uses phospholipids as acyl donors to produce diacylglycerol, which are substrates for DGAT 
enzymes (Besterman et al., 1986). It may be that both situations exist, but whether DGAT-
associating proteins are acyl competitors or acyl donors depends on the actual physiological 
needs. We could use co-immunoprecipitation technique to determine the interactions between 
these proteins and DGAT enzymes. Furthermore, we could overexpress or silence them to 
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examine their effects on TG production and other lipid synthesis. These studies could reveal the 
functional roles of the proteins. 
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